



Pre-pregnancy body mass index and the risk of adverse outcome in type 1 diabetic pregnancies- a population based cohort study.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000601
Article Type:	Research
Date Submitted by the Author:	10-Nov-2011
Complete List of Authors:	<p>Persson, Martina; Karolinska Institute, Department of Clinical Science, Intervention and Technology Pasupathy, Dharmindra; Division of Women's Health, NIHR Biomedical Research Centre, Kings Health's Partners, King's College London, Maternal and Fetal Medicine Hanson, Ulf; Department of Woman and Child Health, Uppsala University, Sweden. Westgren, Magnus; Karolinska Institute, Department of Clinical Science, Intervention and Technology Norman, Mikael; Karolinska Institute, Department of Clinical Science, Intervention and Technology</p>
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology
Keywords:	Diabetes in pregnancy < DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY, Fetal medicine < OBSTETRICS

SCHOLARONE™
Manuscripts

1
2
3
4
5 *Pre-pregnancy body mass index and the risk of adverse outcome in type 1 diabetic*
6 *pregnancies - a population based cohort study.*
7
8
9

10
11 Martina Persson MD ¹, Dharmintra Pasupathy MSc PhD ², Ulf Hanson PhD ³, Magnus
12 Westgren, PhD ¹Mikael Norman, PhD ¹
13

14
15
16
17
18 ¹Department of Clinical Science, Intervention and Technology, Karolinska Institute,
19 Stockholm, Sweden ² Division of Women's Health, NIHR Biomedical Research Centre,
20 Kings Health's Partners, King's College London, UK ³Department of Woman and Child
21 Health, Uppsala University, Sweden.
22
23
24
25
26
27

28
29 Short running title: Overweight in type 1 diabetic pregnancies
30

31
32 Word count: 3,675 words (abstract 300 words) excluding references, 1 figure and 4 tables
33
34
35
36
37
38

39 Corresponding author:

40
41 Martina Persson
42
43
44

45 Address: Sachs' Children's Hospital
46

47 S-118 83 Stockholm, Sweden
48

49 Telephone number: +46 8-73 980 5959
50

51 Fax number: + 46 8-7169564
52

53 Email: Martina.Persson@ki.se
54
55
56
57
58
59
60

Article summary

Article focus

To assess the risk of obstetric and perinatal complications in overweight and obese women with and without type 1 diabetes (T1DM).

Key findings

- High pre-pregnancy BMI is an important risk factor for adverse outcome in type 1 diabetic pregnancies.
- The combined effect of both type 1 diabetes and overweight or obesity constitutes the greatest risk.
- T1DM is a significant effect modifier of the association between BMI and LGA, major malformations and preeclampsia ($p < 0.001$).

Strengths and Limitations

The present study is to our knowledge, the first to present risk estimates of several obstetric and perinatal complications in women with type 1 diabetes, stratified by BMI category and compared with a non-diabetic reference population. The population based study design, including a very large cohort of T1DM pregnancies offers a unique possibility to provide solid data on risks associated with high BMI, including comparatively rare outcomes such as perinatal mortality. A potential limitation is that the study design did not allow assessment of the impact of maternal glycaemic control on the association between exposure and outcome.

Abstract

Objective To assess the risk of perinatal complications in overweight and obese women with and without type 1 diabetes (T1DM).

Research Design Prospective population-based cohort study.

Setting This study was based on data from the Swedish Medical Birth Registry from 1998 - 2007.

Participants 3,457 T1DM and 764,498 non-diabetic pregnancies were included. T1DM was identified based on ICD code O24.0. Mothers were categorized according to pre-pregnancy body mass index (BMI: weight in kg/height in m²) as normal weight (BMI 18.5-24.9), overweight (BMI 25-29.9) or obese (BMI ≥30). Only women with singleton pregnancies and with data on BMI were included.

Outcomes The primary outcome was large-for-gestational age (LGA: birth weight >90th percentile) infants. Secondary outcomes were major malformations, preeclampsia (PE), preterm delivery, perinatal mortality, delivery by Cesarean section and neonatal overweight. Logistic regression analysis was performed with normal weight non-diabetic women as the reference category and also within the diabetic cohort with normal weight type 1 diabetic women as the reference. The odds ratios (OR) were adjusted for ethnicity, maternal age, height, parity, smoking and chronic hypertension.

Results 35% of women with T1DM were overweight and 18% were obese, as compared to 26% and 11%, respectively, in non-diabetic pregnancies. The incidences of adverse outcome increased with greater BMI category. As compared with non-diabetic normal weight women, the adjusted OR for obese T1DM for LGA was [adj OR: 13.26 (11.27-15.59)], major malformations [adj OR 4.11 (2.99-5.65)] and PE [adj OR: 14.19 (11.50-17.50)]. T1DM was a significant effect modifier of the association between BMI and LGA, major malformations and PE (p<0.001).

Conclusion High pre-pregnancy BMI is an important risk factor for adverse outcome in type 1 diabetic pregnancies. The combined effect of both type 1 diabetes and overweight or obesity constitutes the greatest risk. It seems prudent to strive towards normal pre-pregnancy BMI in women with T1DM.

Introduction

Body mass index (BMI) has increased among fertile women in many countries, including Sweden (1). Maternal overweight and obesity are well known risk factors for adverse pregnancy outcome. High pre-pregnancy BMI has been associated with increased risk for stillbirth, foetal malformations, large-for-date neonates, neonatal and infant death, pregnancy induced hypertension and preeclampsia, maternal diabetes, delivery by Cesarean section as well as increased numbers of days spent in hospital for both mother and infant (2-11). The pathophysiological mechanism behind the increased risk of adverse pregnancy outcome in obese women is not fully understood. Increased insulin resistance and a state of inflammation associated with obesity (12) are likely important contributing factors.

Given the links between overweight, insulin resistance and adverse pregnancy outcome, any additional pregnancy risks in overweight women with diabetes are important to disclose, especially since overweight and obesity are more prevalent among diabetic women than in the general obstetric population (13). Increased risks of neonatal and maternal morbidity have been reported in overweight and obese women with gestational diabetes (14-16). In contrast, data is very limited regarding the impact of high maternal BMI on the risk of adverse pregnancy outcome in women with type 1 diabetes. An interaction between maternal diabetes, including both pre-gestational and gestational diabetes, and obesity has been suggested to increase the risk of malformations in the offspring (17). However, the majority of women in

1
2
3
4 that study had gestational diabetes and no separate analysis was performed in women with
5
6 type 1 diabetes.
7
8
9

10
11
12
13 The aim of the present study was to analyse the association between maternal overweight and
14 obesity and the risk of fetal and obstetric complications in type 1 diabetic pregnancies, with
15 special reference to the high and increasing incidence of large-for-gestational age infants (13).
16
17 This study includes a large national cohort of more than 3,000 type 1 diabetic pregnancies and
18 the risk of adverse outcome in relation to maternal BMI was also compared with non- diabetic
19 pregnancies. Our hypothesis was that maternal overweight/obesity and maternal type 1
20 diabetes have independent impact on the risk of adverse outcome and that the combination of
21 the two constitutes the greatest risk.
22
23
24
25
26
27
28
29
30
31
32

33 **Research design, material and methods**

34
35 This population based cohort study was based on data from the Swedish Medical Birth
36 Registry (MBR). The MBR prospectively collects information on maternal medical history,
37
38 obstetric and neonatal diagnoses and covers more than 99% of all pregnancies in Sweden. The
39
40 quality of data has been found high (18).
41
42
43

44 Maternal and neonatal diagnoses are classified according ICD-10. All diagnoses are made by
45 a physician before hospital discharge and copies of the records are forwarded to the MBR.
46
47

48 Maternal characteristics included in the present study were mother's age, parity, pre-
49 pregnancy weight, height, chronic hypertension, smoking habits, and whether the mother was
50 born in one of the Nordic countries (Sweden, Finland, Denmark, Norway or Iceland) or
51 elsewhere. Chronic hypertensive disease ICD-10: I10 or O10.0) was defined as blood pressure
52 above 140/90 mmHg diagnosed before pregnancy or before 20 weeks of gestation. Maternal
53
54
55
56
57
58
59
60

1
2
3
4 height and pre-pregnancy weight were recorded by recall and body mass index (BMI) was
5
6 calculated as weight in kg divided by the square of the height in meters. Exposure in women
7
8 with and without T1DM was defined as overweight ($BMI \geq 25-29.9 \text{ kg/m}^2$) or obese ($BMI \geq 30$
9
10 kg/m^2) and pregnancy outcomes were compared with that of normal weight women (BMI
11
12 $18.5-24.9 \text{ kg/m}^2$). Women with $BMI < 18.5 \text{ kg/m}^2$ (under-weight) and records with missing
13
14 data on BMI were excluded as well as records with extreme values on maternal age (< 13 or
15
16 > 54 years) maternal weight (< 40 or $> 200 \text{ kg}$) or maternal height (< 120 or $> 200 \text{ cm}$). We
17
18 applied the same limits for data acceptance of birth weight and birth length as in the Swedish
19
20 Perinatal Quality Registry: i.e. records with birth weight < 200 or > 9998 grams or birth
21
22 length < 15 or $> 65 \text{ cm}$, were excluded.
23
24
25
26
27
28

29 ***Study cohort***

30
31 Infants from singleton pregnancies and born to mothers with type 1 diabetes in Sweden
32
33 between 1998 and 2007 were included, in total $n=3,457$. Type 1 diabetic pregnancies were
34
35 identified based on ICD10 code O240.
36
37
38
39

40 ***Non-diabetic cohort***

41
42 The reference group ($n= 764,498$) included all singleton pregnancies to mothers without a
43
44 diagnosis of diabetes (based on ICD 10 codes type 1 diabetes: O240, type 2 diabetes all codes
45
46 starting with E11 and E 177-119, O241: or gestational diabetes codes O244 A, B, X) and born
47
48 in the same time period as the study cohort. Percentiles for birth weight were based on all live
49
50 born, singleton infants, without major malformations, to mothers without a diagnosis of
51
52 diabetes. Birth weight percentiles were adjusted for sex and gestational age.
53
54
55
56
57

58 ***Primary outcome***

1
2
3
4 Foetal macrosomia, i.e. giving birth to a large-for-gestational age (LGA) infant was the
5 primary outcome of this study (LGA was defined as a birth weight >90th percentile adjusted
6 for sex and gestational age).
7
8
9

10 11 12 13 *Secondary outcomes*

14
15 Secondary outcomes were major malformations, preeclampsia, preterm delivery, perinatal
16 mortality, delivery by Cesarean section (emergency and elective) and neonatal overweight.
17 Major malformations were pre-defined in the MBR as fatal or potentially life threatening
18 malformations or if the malformation would likely lead to a serious handicap or major
19 cosmetic defect if not surgically corrected. Preeclampsia was defined as a blood pressure
20 above 140/90 mmHg after 20 weeks of gestation and proteinuria (at least 0.3 g/day or > 1+ on
21 a urine dipstick, ICD-10 codes: O14.0, O14.1 and O15). Preterm birth was defined as delivery
22 before 37 gestational weeks. Perinatal mortality was defined as intrauterine death after the
23 28th week of gestation or death during the first week of postnatal life. Neonatal overweight
24 was defined as birth weight and ponderal index (PI: birth weight in grams/length cm³) above
25 the 90th percentile adjusted for sex and gestational age.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 43 *Statistical methods*

44 Comparison between groups were made using Kruskal Wallis test for continuous data and χ^2
45 test and χ^2 test for trend for binary and categorical data as appropriate. Unconditional logistic
46 regression was used to explore associations between maternal BMI categories and adverse
47 outcomes with normal weight (BMI 18.5-24.9 kg/m²) women as the reference category as
48 follows: the odds ratios of adverse outcomes in relation to BMI category were estimated in
49 women with type 1 diabetes with 1) normal weight women with type 1 diabetes as reference
50 category and 2) with normal weight non-diabetic women as reference category and in non-
51
52
53
54
55
56
57
58
59
60

1
2
3
4 diabetic women with normal weight non-diabetic women as reference category. Crude and
5
6 adjusted odds ratios (OR) were calculated. The following variables were included in the final
7
8 regression model for LGA as possible confounders because of their established association
9
10 with the primary outcome: Nordic origin (yes/no), maternal age, height, parity, smoking and
11
12 chronic hypertension. The final regression models for the secondary outcomes included
13
14 covariates significantly associated with the outcomes in univariate analysis. Missing indicator
15
16 variables were used for maternal age and height. The likely hood ratio test was used to
17
18 explore potential interaction between BMI categories and T1DM for the risk of the adverse
19
20 outcomes. A p-value <0.05 was considered significant. All statistical analyses were performed
21
22 using STATA 10.1 SE.
23
24
25
26
27
28

29 **Results**

30
31 Between 1998 and 2007, there were 947,096 deliveries in Sweden, including 4,208 (0.4%)
32
33 deliveries to mothers with type 1 diabetes. Of all pregnancies, we excluded 441 records
34
35 (0.05%) with extreme values on maternal age, maternal weight or height. No records were
36
37 excluded due to extreme values on birth weight but 3,402 records were missing for this
38
39 variable. We excluded 90 records (0.01%) due to extreme values on birth length and 14,544
40
41 were missing for birth length. In women with type 1 diabetes, 652 records (15%) were
42
43 excluded due to missing data on maternal BMI or BMI<18.5 and 116 (2.8%) due to multiple
44
45 pregnancies. The final study cohort comprised 3,457 infants (1,758 male infants, 51%) born
46
47 to mothers with type 1 diabetes. The reference population included 764,498 singleton
48
49 pregnancies to mothers without a diagnosis of diabetes, excluding 28,018 records from
50
51 multiple pregnancies and 147,835 records with missing data on maternal BMI or BMI<18.5.
52
53
54
55
56
57
58
59
60

1
2
3
4 Reference percentiles for birth weight, birth length and ponderal index were formed using
5 records from all non-diabetic pregnancies and excluding stillborn infants (0.31%), infants
6 with major malformations (1.84%) and multiple pregnancies (3.01%).
7
8
9

10 11 12 *Maternal and infant characteristics*

13
14 Mothers with type 1 diabetes had a significantly higher median pre-pregnancy BMI (25.1
15 kg/m²) compared to the non-diabetic group (23.6 kg/m²), (p<0.001). In the type 1 diabetic
16 cohort, 35% (n= 1,195) of women were overweight and 18% (n=618) were obese as
17 compared with 26% (n=200,600) and 11% (n=82,331), respectively, in the non-diabetic
18 population, Figure 1. Women with type 1 diabetes were also more often of Nordic origin, had
19 a higher prevalence of chronic hypertension and smoking during the first trimester compared
20 to women without diabetes (p-value for all comparisons <0.01). Infants to mothers with
21 diabetes type 1 were born at a significantly lower median gestational age and preterm birth
22 was four times as common compared to non-diabetic offspring (p-value for all comparisons
23 <0.001). The median birth weight was significantly higher in infants to mothers with type 1
24 diabetes than in the reference group, Table 1.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 *Adverse outcomes in relation to body mass index category*

44 Overall, the incidence of all adverse outcomes was significantly higher in women with type 1
45 diabetes, irrespective of BMI category. The incidence of the primary outcome was highest in
46 obese women; however the difference did not reach statistical significance within the diabetes
47 cohort. The incidence of all secondary outcomes was highest in obese women with and
48 without type 1 diabetes, except for PMR in type 1 diabetic pregnancies with the highest
49 recorded frequency in overweight women. Within the non-diabetic pregnancies, the incidence
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 of all outcomes increased significantly with greater BMI category (chi square test for trends
5
6 for all outcomes $p < 0.001$), Table 2.
7
8

9
10
11 There was a similar pattern of increasing odds ratio for adverse outcome with greater BMI
12 category in women with and without type 1 diabetes. Inclusion of maternal covariates in the
13 regression models did not significantly change these estimates. Relative to a normal weight
14 non-diabetic woman, the adjusted OR for the risk of having a LGA infant in overweight or
15 obese women with type 1 diabetes was approximately 13, as compared with approximately 2
16 in overweight and obese non-diabetic women, Table 3. In relation to a normal weight woman
17 without diabetes, obesity in women with type 1 diabetes was associated with an adjusted OR
18 for major malformation of [4.11 (2.99-5.65)] as compared with [1.15 (1.09-1.22)] in women
19 with obesity only. Compared with a normal weight non-diabetic woman, the adjusted odds
20 ratios for PE in a woman with type 1 diabetes of normal weight was [7.17 (6.04-8.50)] and in
21 combination with overweight [9.91 (8.61-11.40)] and in the obese woman [14.19 (11.50-
22 17.50)]. The corresponding estimates for a non-diabetic woman with overweight or obesity
23 were [1.74(1.69-1.80)] and [3.37 (3.25-3.49)], respectively. The OR for Cesarean section
24 increased with BMI category in both women with and without type 1 diabetes, Table 3.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 Table 4 shows the OR for adverse outcome in women with type 1 diabetes by BMI category
45 with normal weight women with type 1 diabetes as the reference category. In obese women
46 the adjusted OR of major malformations [1.77 (1.18-2.65)] and preeclampsia [1.74(1.35-
47 2.25)] were significantly increased compared with normal weight women. The OR of
48 Cesarean section was significantly increased in both overweight and obese women, Table 4
49
50
51
52
53
54
55
56
57

58 Discussion

59
60

1
2
3
4 This study shows that high maternal pre-pregnancy BMI is a very important risk factor for
5 adverse pregnancy outcome in women with and without type 1 diabetes. High maternal BMI
6 and type 1 diabetes are independent risk factors for maternal and perinatal complications.
7
8
9 However, type 1 diabetes remains a stronger risk factor for adverse outcome than obesity. The
10 risk of adverse outcome in women with concomitant type 1 diabetes and obesity exceeds that
11 of either condition alone, indicating synergism between the two exposures. Obesity in type 1
12 diabetes is associated with significantly increased risk of PE, major malformations and
13 Cesarean section as compared with type 1 diabetic women with normal BMI.
14
15
16
17
18
19
20
21
22
23

24 The prevalence of overweight and obesity in pregnant women is increasing in Sweden and
25 worldwide (1, 12) and the harmful effects of high maternal BMI on pregnancy outcome are
26 well established in the general obstetric population (2-11). On the other hand, data on the
27 potential association between high maternal BMI and adverse pregnancy outcome in women
28 with type 1 diabetes is scarce (17, 19-20). In a cohort of 46 women with type 1 diabetes and
29 nephropathy, maternal overweight was identified as an important risk factor for poor
30 pregnancy outcome (19). In mixed populations of women with pre-gestational diabetes,
31 maternal obesity has been associated with pregnancy complications (20) and increased risk of
32 birth defects (17). These two studies however, do not separate women with diabetes type 1
33 from those with diabetes type 2 and do not include any comparable data from a non-diabetic
34 reference population.
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 The present study is to our knowledge, the first to present risk estimates of obstetric and
50 perinatal complications in a large cohort of women with exclusively type 1 diabetes, stratified
51 by BMI category and compared with a non-diabetic reference population. The large sample
52 size enabled risk estimation of rare outcomes such as perinatal mortality and major
53 malformations in relation to subgroups of maternal BMI. The population based study design
54
55
56
57
58
59
60

1
2
3
4 provides unanimous risk estimates for overweight and obese women with and without type 1
5 diabetes. The vast majority of our study population is of Nordic origin. The study population
6 is also homogenous with respect to medical care in pregnancy. In Sweden, healthcare is free
7 of charge as well as insulin, test strips for home monitoring of glucose and equipment for
8 insulin administration. The care of pregnant women with type 1 diabetes is uniform over the
9 whole country and pregnancy outcome does not differ with geographical area (13).
10
11
12
13
14
15
16
17
18
19

20 Some limitations with the present study should be noted. Body mass index was calculated
21 from recalled data on pre-pregnancy weight and height. Women tend to underestimate their
22 weight and it has been demonstrated that this bias increases directly with the degree of
23 overweight (21). A potential misclassification of women to lower BMI categories would lead
24 to an underestimation of our findings of increased risks associated with high maternal BMI.
25 The Swedish MBR does not collect data on maternal glycaemic control, duration of diabetes,
26 insulin regimens nor data on diet and physical activity. Consequently, the impact of diet,
27 physical activity and level of control on the risk of adverse outcome could not be assessed. It
28 is plausible that the achieved level of metabolic control differed between normal weight,
29 overweight and obese type 1 diabetic women. In a study on pregnancies complicated by
30 gestational diabetes, the fasting glucose levels were significantly higher in obese compared
31 with overweight and normal weight women (14). However, results from the HAPO study
32 confirm that maternal BMI and glycaemia exert independent effects on the risk of adverse
33 pregnancy outcome (2).
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 In the present study, obese women with type 1 diabetes had significantly increased risks of
54 major malformations and preeclampsia as compared with normal weight women with type 1
55 diabetes. This is in line with the finding of an interaction between maternal diabetes and
56
57
58
59
60

1
2
3
4 obesity on the risk of adverse outcome in a mixed population of women with different types
5
6 of diabetes (17). However, the increased risk of major malformations in relation to BMI in the
7
8 present analysis should be interpreted with caution as maternal overweight and obesity rend
9
10 ultrasound assessment of fetal anatomy difficult (22) and we do not have data on the number
11
12 of induced abortions due to malformations. Maternal hyperglycemia in early pregnancy is a
13
14 well known risk factor for major malformations and preeclampsia (23). Obesity is associated
15
16 with increased insulin resistance (12) and one could speculate that women with obesity had a
17
18 poorer level of control in early pregnancy than women with normal or slightly elevated BMI.
19
20 In line with previous studies, we found increased risks of PE and major malformations in
21
22 obese non diabetic women (5, 6, 10). In the present study, the risks of these complications
23
24 were also significantly elevated in non- diabetic women with overweight. Obesity is
25
26 associated with decreased insulin sensitivity and already slightly elevated levels of fasting
27
28 glucose, within the upper normal range, are associated with increased risk of preeclampsia in
29
30 women without diabetes (24). In Sweden, there is no uniform screening for gestational
31
32 diabetes. It is possible that the increased risk of PE and major malformations in overweight
33
34 and obese women in the reference group is partly due to undetected cases of impaired glucose
35
36 tolerance or diabetes. Interestingly, maternal pre pregnancy BMI has been demonstrated as a
37
38 stronger predictor of major malformations than severity of gestational diabetes (25).
39
40
41
42
43
44
45

46
47 In women with type 1 diabetes, the incidence of LGA was very high in all weight classes and
48
49 increased with greater BMI category. However, the odds ratio for an LGA outcome did not
50
51 differ significantly with BMI category, as opposed to in non-diabetic women. On the contrary,
52
53 the risk of delivering a disproportionate LGA infant (PI > 90th percentile) was significantly
54
55 increased in obese women within the type 1 diabetic cohort. In accordance with the study by
56
57 Ehrenberg our findings indicate that maternal overweight is an important risk factor for LGA,
58
59
60

1
2
3
4 but maternal diabetes has an even greater impact (26). A possible contributing factor to this
5
6 finding could also be the increasing prevalence of preeclampsia with greater BMI category.
7
8
9

10
11 This study confirms the observations in non-diabetic pregnancies (2-5) that increasing
12
13 maternal BMI is associated with increased risk of delivery by Cesarean section also in women
14
15 with type 1 diabetes. The increased incidence of complications such as preeclampsia and
16
17 LGA in these groups most likely contributes to this finding.
18
19

20
21
22 The majority of perinatal deaths were stillbirths in all BMI categories and in both women
23
24 with and without type 1 diabetes. The risk of perinatal mortality was independent of BMI
25
26 category within the type 1 diabetic cohort but increased significantly with higher BMI in the
27
28 reference group. This finding is in line with previous studies, reporting increased risk of both
29
30 stillbirth and neonatal mortality in obese, non-diabetic women even after adjusting for
31
32 maternal and perinatal risk factors (7, 8, 9). The lack of a significantly increased risk of
33
34 perinatal mortality with increasing BMI category within the diabetes cohort, indicate that
35
36 diabetes is a stronger risk factor for perinatal mortality than maternal overweight/obesity.
37
38
39

40
41
42 In the present study, we found an increasing risk of preterm delivery with greater BMI
43
44 category in both women with and without type 1 diabetes.
45

46
47 Results from some earlier studies have shown an increased risk of preterm delivery in obese
48
49 non-diabetic women (3, 4) while others have reported the opposite association (2, 5).
50

51
52
53 It is hypothesized that the increased risk of pregnancy complications in overweight and obese
54
55 women is due to increased maternal fat mass. In the present study, pre pregnancy BMI was
56
57 used as a proxy for maternal fat mass. This assumption is a potential limitation, however there
58
59
60

1
2
3
4 is a strong correlation ($r^2= 0.86$) between pre pregnancy BMI and maternal fat mass in women
5
6 without diabetes (27). More importantly, BMI does not provide information on the
7
8 localization of fat mass. One hypothesized link between high maternal pre pregnancy BMI
9
10 and increased risk of adverse outcome is the visceral fat mass. The visceral fat mass is
11
12 associated with increased insulin resistance, inflammation and lipotoxicity with potential
13
14 harmful effects on maternal vascular and placental function and fetal development (28). The
15
16 pathophysiological mechanism behind the increased risk of adverse pregnancy outcome in
17
18 overweight/obese mothers is not clear but is most likely complex. Genetic- and
19
20 socioeconomic factors, maternal diet and physical activity are probable contributing factors.
21
22 However, the similar pattern, in both women with and without type 1 diabetes, with increased
23
24 risk of adverse outcome with higher maternal BMI implies that BMI per se is an important
25
26 risk factor to address. It is reasonable to assume that preventive measures, aiming at normal
27
28 pre pregnancy BMI, may reduce the risk of complications in type 1 diabetic pregnancies.
29
30
31
32
33
34
35

36 In conclusion, this population based study on more than 3000 type 1 diabetic pregnancies
37
38 demonstrates a strong association between maternal pre-pregnancy BMI and elevated risk of
39
40 adverse pregnancy outcome. Type 1 diabetes in combination with overweight or obesity
41
42 constitutes a higher risk than either condition alone. Striving towards normal pre pregnancy
43
44 BMI in women with type 1 diabetes could hopefully reduce the risk of adverse outcome.
45
46
47
48

49 **Acknowledgement**

50 This study was supported by the Swedish Order of Freemasons and the Stockholm County
51
52 Council. DP was funded by the National Institute of Health Research (NIHR), UK and the
53
54 Tommy's Charity. The funding consisted of salary for the researchers MP and DP. We
55
56 appreciate the help from the Swedish Medical Birth Registry to provide us with data.
57
58
59
60

Disclosure of interest

The authors have no potential conflicts of interest.

Author contributions

MP. DP.UH.MW.MN; contributions of design and interpretation of data

MP. UH; Data acquisition

MP. DP; Data analyses

MP. DP.UH.MW. MN; Interpretation of results

MP. MN; Drafted the manuscript

MN; Handled funding and supervision

MP. DP. UH. MW.MN; Critical revision of the manuscript and final approval of the version to be published

Ethics Approval

This study was approved by the Regional Ethical Review Board in Uppsala, Sweden. Date of approval: 22/7 2009, reference number: 2009/187

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Data sharing statement

No additional data available.

.

Strobe

This manuscript was written according to the guidelines given by STROBE. The study hypothesis arose before inspection of the data.

References:

- 1) Surkan P, Chung-Cheng Hsieh, Johansson A.L.V et al.Reasons for Increasing Trends in Large for Gestational Age Births S Obstetrics and Gynecology 2004;104:4
- 2) HAPO Study Cooperative Research Group. Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) Study: associations with maternal body mass index. BJOG;2010;117:575-584
- 3) Callaway L.K, Prins J.B, Chang A.M et al.The prevalence and impact of overweight and obesity in an Australian obstetric population. MJA;2006;2:56-59
- 4) Heslehurst N, Simpson H, Ells L.J et al.The impact of maternal BMI status on pregnancy outcomes with immediate short-term obstetric resource implications:a meta-analysis. Obesity Reviews;2008;9:635-683
- 5) Athukorala C, Rumbold A.R, Willson K.J et al.The risk of adverse pregnancy outcomes in women who are overweight or obese. BMC Pregnancy and Childbirth;2010;10:56
- 6) Stothard K.J, Tennant P.W.G, Bell R et al. Maternal Overweight and Obesity and the Risk of Congenital Anomalies. A systematic Review and Meta-analysis. JAMA;2009;301:636-650
- 7) Kristensen J, Vestergaard M, Wisborg K et al.Pre-pregnancy weight and the risk of stillbirth and neonatal death. BJOG;2005;112:403-408
- 8) Nohr E.A, Vaeth M, Bech B.H et al.Maternal Obesity and Neonatal Mortality According to Subtypes of Preterm Birth. Obstet Gynecol;2007;110:1083-1090
- 9) Cnattingius S, Bergström R, Lipworth L et al. Prepregnancy weight and the risk of adverse pregnancy outcomes. N Engl J Med ;1998;338:147-152.
- 10) O'Brien TE, Ray JG, Chan WS. Maternal body mass index and the risk of preeclampsia: a systematic overview. Epidemiology;2003;14:368-374

- 1
2
3
4
5 11) Chen A, Feresu S.A, Fernandez C et al. Maternal Obesity and the Risk of Infant Death in
6
7 the United States. *Epidemiology*;2009;20:74-81
8
9
10 12) Catalano P. Obesity, insulin resistance, and pregnancy outcome.
11
12 *Reproduction*;2010;140:365-371
13
14 13) Persson M, Norman M, Hanson U. Obstetric and perinatal outcomes in type 1 diabetic
15
16 pregnancies - a large, population-based study. *Diabetes Care* 2009;32:2005-9
17
18 14) Roman AS, Rebarber A, Fox N.S et al. The effect of maternal obesity on pregnancy
19
20 outcomes in women with gestational diabetes.
21
22 *J Matern Fetal Neonatal Med*;2011;24(5):723-727
23
24 15) Yogev Y, Langer O. Pregnancy outcome in obese and morbidly obese gestational diabetic
25
26 women. *European Journal of Obstetrics and Gynecology and Reproductive*
27
28 *Biology*;2008;137:21-26
29
30 16) Langer O, Yogev Y, Xenakis E.M.J et al. Overweight and obese in gestational
31
32 diabetes: The impact on pregnancy outcome. *Am J Obstet Gynecol*;2005;192:1768-1776
33
34 17) Moore L.L, Singer M.R, Bradlee M.L et al. A prospective study of the risk of congenital
35
36 defects associated with maternal obesity and diabetes mellitus.
37
38 *Epidemiology*;2000;11:689-694
39
40 18) Cnattingius S, Ericson A, Gunnarskog J et al. A quality study of a medical birth registry.
41
42 *Scand J Soc Med*; 1990;18:143-148
43
44 19) Yogev Y, Chen R, Ben-Haroush A et al. Maternal overweight and pregnancy outcome in
45
46 women with type 1 diabetes mellitus and different degrees of nephropathy. *The J of*
47
48 *Maternal-Fetal and Neonatal Medicine*;2010;23:999-1003
49
50 20) Ray J.G, Vermeulen M.J, Shapiro J.L et al. Maternal and neonatal outcomes in
51
52 pregestational and gestational diabetes mellitus, and the influence of maternal obesity and
53
54 weight gain: the DEPOSIT study. *Q J Med*;2001;94:347-356
55
56
57
58
59
60

- 1
2
3
4 21) Rowland ML. Self-reported weight and height. *Am J Clin Nutr*;1990;52(6):1125-1133
5
6 22) Dashe JS, McIntire DD, Twickler DM. Maternal obesity limits the ultrasound evaluation
7
8 of fetal anatomy. *J Ultrasound Med*;2009;28(8):1025-1030
9
10 23) Taylor R, Davidson J.M. Type 1 diabetes and pregnancy. *BMJ*;2007;334:742-5
11
12 24) The HAPO study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy
13
14 Outcomes. *N Eng J of Medicine*;2008;358:1991
15
16 25) Garcia-Patterson A, Erdozain L, Ginovart G et al. In human gestational diabetes mellitus
17
18 congenital malformations are related to pre-pregnancy body mass index and to severity of
19
20 diabetes. *Diabetologia*; 2004;47:509-514
21
22 26) Ehrenberg H.M, Brian M.M, Catalano P. The influence of obesity and diabetes on the
23
24 prevalence of macrosomia. *Am J Obstet Gynecol*;2004;191:964-968
25
26 27) Sewell MF, Huston-Presley L, Amini SB et al. Body mass index: a true indicator of body
27
28 fat in obese gravidas. *J Reprod Med*;2007;52(10):907-11
29
30 28) Jarvie E, Hauguel-de-Mouzon S, Nelson S, Sattar N, Catalano P, Freeman D J.
31
32 Lipotoxicity in obese pregnancy and its potential role in adverse pregnancy outcome and
33
34 obesity in the offspring. *Clinical Science*;2010;119:123-12
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1) Maternal characteristics, type 1 diabetes and reference population

Numbers and percentages

	Type 1 diabetes N=3,457	Non-diabetic population N=764,498
Maternal characteristics		
Nordic, n (%)	3,194 (92)	643,608 (84)
Maternal age, years (median, IQR)	30 (27-34)	30(27-33)
Smoking first trimester, n (%)	384 (11)	72,766 (10)
Primipara, n (%)	1,559 (45)	337,199 (44)
BMI, kg/m ² (median, IQR)	25.1 (23.0-28.4)	23.6 (21.6-26.4)
Over weight (BMI ≥ 25-29.9), n(%)	1,195 (35%)	200,600 (26%)
Obese (BMI ≥30), n(%)	618 (18%)	82,331 (11%)
Height, cm (median,IQR)	167 (162-170)	167 (162-170)
Chronic hypertension, n (%)	92 (2.7)	2,472 (0.32)
Infant characteristics		
Male, n (%)	1,758 (51%)	393,324 (51%)
Gestational age, weeks (md,IQR)	38 (37-39)	40 (39-41)
Preterm delivery (n, %)	741 (21%)	35,878 (4.7%)
Birth weight, g (md,IQR)	3805 (3350-4265)	3575 (3240-3915)
Birth length, cm (md,IQR)	51 (49-52)	51 (49-52)
LGA, BW >90 percentile, n (%)	1,694 (49)	81,142 (11)
AGA, BW 10-90 percentile, n (%)	1,661 (48%)	614,784 (80%)
SGA, BW <10 percentile, n (%)	109 (3.2%)	76,214 (10)

Table 2) Outcomes, type 1 diabetes and non-diabetic population

Numbers and percentages

	BMI 18.5-24.9	BMI 25-29.9	BMI≥30	P value
LGA				
Type 1 diabetes	778 (47)	603 (50)	313 (51)	0.170
Non-diabetic	39,265 (8.2)	26,828 (13)	15,049 (18)	<0.001
Major malformations				
Type 1 diabetes	65 (4.0)	44 (3.7)	41 (6.6)	0.008
Non-diabetic	8,186 (1.7)	3,736 (1.9)	1,610 (2.0)	<0.001
Preelampsia				
Type 1 diabetes	222 (14)	185 (15)	114 (18)	0.012
Non-diabetic	9,872 (2.1)	6,529 (3.3)	4,810 (5.8)	<0.001
Preterm delivery				
Type 1 diabetes	322 (20)	275 (23)	144 (23)	0.041
Non-diabetic	21,714 (4.5)	9,464 (4.7)	4,700 (5.7)	<0.001
Perinatal mortality				
Type 1 diabetes	14 (0.85)	15 (1.3)	6 (0.97)	0.566
Non-diabetic	1,554 (0.32)	948 (0.47)	593 (0.72)	<0.001
Cesarean section				
Type 1 diabetes	748 (46)	639 (53)	362 (59)	<0.001
Non-diabetic	64,131 (13)	34,081 (17)	18,166 (22)	<0.001
Neonatal overweight				
Type 1 diabetes	351 (21)	288 (24)	166 (27)	0.016
Non-diabetic	15,359 (3)	10,430 (5)	6,466 (8)	<0.001

*Chi square test, Kruskal Wallis test, Chi square test for trends

Table 3) Crude and Adjusted* Odds ratios (CI) for outcomes in T1DM and non-diabetic population

	Non-diabetic BMI 18.5-24.9	T1DM BMI 18.5-24.9	BMI 25-29.9	BMI≥30	Interaction# P value
LGA, T1DM					
Crude	1.0	10.16 (9.10-11.36)	12.40 (11.22-13.70)	12.29 (10.50-14.40)	<0.001
Adjusted	1.0	10.72 (9.56-12.01)	13.55 (12.23-15.02)	13.26 (11.27-15.59)	<0.001
LGA, ref					
Crude	1.0	-	1.74 (1.71-1.77)	2.52 (2.47-2.57)	<0.001
Adjusted	1.0	-	1.76 (1.73-1.79)	2.60 (2.55-2.66)	<0.001
Major malformations, T1DM					
Crude	1.0	2.28 (1.71-3.04)	2.34 (1.81-3.02)	4.11 (2.99-5.65)	0.03
Adjusted	1.0	2.28 (1.71-3.04)	2.34 (1.81-3.03)	4.11 (2.99-5.65)	0.03
Major malformations, ref					
Crude	1.0	-	1.10 (1.06-1.14)	1.15 (1.09-1.22)	0.03
Adjusted	1.0	-	1.10 (1.06-1.14)	1.15 (1.09-1.22)	0.03
Preeclampsia, T1DM					
Crude	1.0	7.12 (6.02-8.42)	9.30 (8.11-10.67)	11.23 (9.15-13.77)	<0.001
Adjusted	1.0	7.17 (6.04-8.50)	9.91 (8.61-11.40)	14.19 (11.50-17.50)	<0.001
Preeclampsia, ref					
Crude	1.0	-	1.61 (1.56-1.66)	2.96 (2.86-3.07)	<0.001
Adjusted	1.0	-	1.74 (1.69-1.80)	3.37 (3.25-3.49)	<0.001
Preterm delivery, T1DM					
Crude	1.0	4.86 (4.22-5.60)	6.23 (5.53-7.02)	6.39 (5.30-7.71)	0.16
Adjusted	1.0	4.72 (4.09-5.44)	5.98 (5.31-6.74)	5.97 (4.94-7.21)	0.15
Preterm delivery, ref					
Crude	1.0	-	1.05 (1.02-1.07)	1.28 (1.24-1.32)	0.16
Adjusted	1.0	-	1.04 (1.02-1.07)	1.26 (1.22-1.30)	0.15
PMR, T1DM					
Crude	1.0	2.55 (1.36-4.76)	3.93 (2.49-6.19)	3.14 (1.40-7.04)	0.29
Adjusted	1.0	2.46 (1.32-4.60)	3.72 (2.36-5.89)	2.86 (1.27-6.44)	0.31
PMR, ref					
Crude	1.0	-	1.47 (1.35-1.59)	2.24 (2.04-2.46)	0.29
Adjusted	1.0	-	1.46 (1.35-1.59)	2.22 (2.03-2.44)	0.31

Cesarean section, T1DM					
Crude	1.0	5.59 (5.00-6.25)	7.09 (6.42-7.83)	9.44 (8.04-11.08)	0.42
Adjusted	1.0	5.69 (5.09-6.37)	7.12 (6.44-7.88)	9.35 (7.95-11.00)	0.36
Cesarean section, ref					
Crude	1.0	-	1.33 (1.31-1.35)	1.84 (1.81-1.88)	0.42
Adjusted	1.0	-	1.34 (1.32-1.36)	1.87 (1.83-1.90)	0.36
Neonatal overweight, T1DM					
Crude	1.0	8.46 (7.39-9.70)	9.93 (8.83-11.17)	11.71 (9.79-14.00)	<0.001
Adjusted	1.0	8.40 (7.32-9.64)	9.86 (8.76-11.11)	11.29 (9.42-13.53)	<0.001
Neonatal overweight, ref					
Crude	1.0	-	1.66 (1.62-1.71)	2.59 (2.51-2.67)	<0.001
Adjusted	1.0	-	1.65 (1.61-1.69)	2.55 (2.48-2.63)	<0.001

*Adjusted for ethnicity, maternal age, height, parity, smoking first trimester, chronic hypertension #Interaction
between BMI category and T1DM


Table 4) Crude and Adjusted* Odds ratios (CI), type 1 diabetes

	BMI 18.5-24.9	BMI 25-29.9	BMI≥30
LGA, T1DM			
Crude	1.0	1.13 (0.98-1.32)	1.14 (0.95-1.37)
Adjusted	1.0	1.18 (1.01-1.38)	1.21 (1.00-1.47)
Major malformations, T1DM			
Crude	1.0	0.93 (0.63-1.37)	1.73 (1.15-2.58)
Adjusted	1.0	0.92 (0.62-1.36)	1.77 (1.18-2.65)
Preeclampsia, T1DM			
Crude	1.0	1.17 (0.95-1.45)	1.45 (1.13-1.86)
Adjusted	1.0	1.21 (0.98-1.50)	1.74 (1.35-2.25)
Preterm delivery, T1DM			
Crude	1.0	1.23 (1.02-1.47)	1.25 (1.00-1.56)
Adjusted	1.0	1.22 (1.02-1.47)	1.25 (1.00-1.56)
PMR T1DM			
Crude	1.0	1.48 (0.71-3.08)	1.14 (0.44-2.98)
Adjusted	1.0	1.47 (0.70-3.03)	1.08 (0.41-2.83)
Cesarean section, T1DM			
Crude	1.0	1.38 (1.19-1.60)	1.69 (1.40-2.04)
Adjusted	1.0	1.37 (1.18-1.60)	1.67 (1.38-2.03)
Neonatal overweight, T1DM			
Crude	1.0	1.17 (0.98-1.40)	1.35 (1.09-1.67)
Adjusted	1.0	1.19 (0.99-1.42)	1.36 (1.09-1.69)

*Adjusted for ethnicity, maternal age, height, parity, smoking first trimester, chronic hypertension

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



Body mass index categories in women with T1DM and in non-diabetic subjects
153x92mm (96 x 96 DPI)

Review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
	X	(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2X	Explain the scientific background and rationale for the investigation being reported
Objectives	3X	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4x	Present key elements of study design early in the paper
Setting	5x	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6x	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
		(b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	7x	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*x	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9x	Describe any efforts to address potential sources of bias
Study size	10x	Explain how the study size was arrived at
Quantitative variables	11x	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12x	(a) Describe all statistical methods, including those used to control for confounding
		(b) Describe any methods used to examine subgroups and interactions
		(c) Explain how missing data were addressed
		(d) If applicable, explain how loss to follow-up was addressed
		(e) Describe any sensitivity analyses
Results		
Participants	13*x	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
		(b) Give reasons for non-participation at each stage
		(c) Consider use of a flow diagram
Descriptive data	14*x	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
		(b) Indicate number of participants with missing data for each variable of interest
		(c) Summarise follow-up time (eg, average and total amount)
Outcome data	15*x	Report numbers of outcome events or summary measures over time
Main results	16x	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
		(b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

Other analyses	17x	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18x	Summarise key results with reference to study objectives
Limitations	19x	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20x	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21x	Discuss the generalisability (external validity) of the study results
Other information		
Funding	22x	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.



Pre-pregnancy body mass index and the risk of adverse outcome in type 1 diabetic pregnancies- a population based cohort study.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000601.R1
Article Type:	Research
Date Submitted by the Author:	05-Jan-2012
Complete List of Authors:	<p>Persson, Martina; Karolinska Institute, Department of Clinical Science, Intervention and Technology Pasupathy, Dharmindra; Division of Women's Health, NIHR Biomedical Research Centre, Kings Health's Partners, King's College London, Maternal and Fetal Medicine Hanson, Ulf; Department of Woman and Child Health, Uppsala University, Sweden., Westgren, Magnus; Karolinska Institute, Department of Clinical Science, Intervention and Technology Norman, Mikael; Karolinska Institute, Department of Clinical Science, Intervention and Technology</p>
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology, Reproductive medicine, obstetrics and gynaecology
Keywords:	Diabetes in pregnancy < DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY, Fetal medicine < OBSTETRICS

SCHOLARONE™
Manuscripts

1
2
3
4
5 PRE-PREGNANCY BODY MASS INDEX AND THE RISK OF ADVERSE OUTCOME IN
6
7 TYPE 1 DIABETIC PREGNANCIES-A POPULATION BASED COHORT
8
9

10
11 Martina Persson MD ¹, Dharmintra Pasupathy MSc PhD ², Ulf Hanson PhD ³, Magnus
12
13 Westgren, PhD ¹Mikael Norman, PhD ¹
14
15

16
17
18 ¹Department of Clinical Science, Intervention and Technology, Karolinska Institute,
19
20 Stockholm, Sweden ² Division of Women's Health, NIHR Biomedical Research Centre,
21
22 Kings Health's Partners, King's College London, UK ³Department of Woman and Child
23
24 Health, Uppsala University, Sweden.
25
26
27

28
29 Short running title: Overweight in type 1 diabetic pregnancies
30
31

32 Word count: 3,773 words (abstract 294 words) excluding references, 1 figure and 4 tables
33
34
35
36
37
38

39 Corresponding author:

40
41 Martina Persson
42
43

44
45 Address: Sachs' Children's Hospital
46
47

48 S-118 83 Stockholm, Sweden
49

50 Telephone number: +46 8-73 980 5959
51

52 Fax number: + 46 8-7169564
53

54 Email: Martina.Persson@ki.se
55
56
57
58
59
60

Article summary

Article focus

To assess the risk of obstetric and perinatal complications in overweight and obese women with and without type 1 diabetes (T1DM).

Key findings

- High pre-pregnancy BMI is an important risk factor for adverse outcome in type 1 diabetic pregnancies.
- The combined effect of both type 1 diabetes and overweight or obesity constitutes the greatest risk.
- T1DM is a significant effect modifier of the association between BMI and LGA, major malformations and preeclampsia ($p < 0.001$).

Strengths and Limitations

The present study is to our knowledge, the first to present risk estimates of several obstetric and perinatal complications in women with type 1 diabetes, stratified by BMI category and compared with a non-diabetic reference population. The population based study design, including a very large cohort of T1DM pregnancies offers a unique possibility to provide solid data on risks associated with high BMI, including comparatively rare outcomes such as perinatal mortality. A potential limitation is that the study design did not allow assessment of the impact of maternal glycaemic control on the association between exposure and outcome.

ABSTRACT

Objective To assess the risk of perinatal complications in overweight and obese women with and without type 1 diabetes (T1DM).

Design Prospective population-based cohort study.

Setting This study was based on data from the Swedish Medical Birth Registry from 1998 - 2007.

Participants 3,457 T1DM and 764,498 non-diabetic pregnancies were included. T1DM was identified based on ICD code O24.0. Mothers were categorized according to pre-pregnancy body mass index (BMI: weight in kg/height in m²) as normal weight (BMI 18.5-24.9), overweight (BMI 25-29.9) or obese (BMI ≥30). Only women with singleton pregnancies and with data on BMI were included.

Primary/secondary outcomes The primary outcome was large for gestational age (LGA: birth weight >90th percentile) infants. Secondary outcomes were major malformations, preeclampsia (PE), preterm delivery, perinatal mortality, delivery by Caesarean section and neonatal overweight. Logistic regression analysis was performed with normal weight non-diabetic women as the reference category and also within the diabetic cohort with normal weight type 1 diabetic women as the reference. The odds ratio's (OR) were adjusted for ethnicity, maternal age, height, parity, smoking and chronic hypertension.

Results 35% of women with T1DM were overweight and 18% were obese, as compared to 26% and 11%, respectively, in non-diabetic pregnancies. The incidences of adverse outcome increased with greater BMI category. As compared with non-diabetic normal weight women, the adjusted OR for obese T1DM for LGA was 13.26 (11.27-15.59), major malformations 4.11 (2.99-5.65) and PE 14.19 (11.50-17.50). T1DM was a significant effect modifier of the association between BMI and LGA, major malformations and PE (p<0.001).

1
2
3
4 **Conclusion** High pre-pregnancy BMI is an important risk factor for adverse outcome in type
5
6 1 diabetic pregnancies. The combined effect of both type 1 diabetes and overweight or obesity
7
8 constitutes the greatest risk. It seems prudent to strive towards normal pre-pregnancy BMI in
9
10 women with T1DM.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Introduction

Body mass index (BMI) has increased among fertile women in many countries, including Sweden (1). Maternal overweight and obesity are well known risk factors for adverse pregnancy outcome. High pre-pregnancy BMI has been associated with increased risk for stillbirth, fetal malformations, large for date neonates, neonatal and infant death, pregnancy induced hypertension and preeclampsia, maternal diabetes, delivery by Caesarean section as well as increased numbers of days spent in hospital for both mother and infant (2-11). The pathophysiological mechanism behind the increased risk of adverse pregnancy outcome in obese women is not fully understood. Increased insulin resistance and a state of inflammation associated with obesity (12) are likely important contributing factors.

Given the links between overweight, insulin resistance and adverse pregnancy outcome, any additional pregnancy risks in overweight women with diabetes are important to disclose, especially since overweight and obesity are more prevalent among diabetic women than in the general obstetric population (13). Increased risks of neonatal and maternal morbidity have been reported in overweight and obese women with gestational diabetes (14-16). In contrast, data is very limited regarding the impact of high maternal BMI on the risk of adverse pregnancy outcome in women with type 1 diabetes. An interaction between maternal diabetes, including both pre-gestational and gestational diabetes, and obesity has been suggested to increase the risk of malformations in the offspring (17). However, the majority of women in that study had gestational diabetes and no separate analysis was performed in women with type 1 diabetes.

The aim of the present study was to analyse the association between maternal overweight and obesity and the risk of fetal and obstetric complications in type 1 diabetic pregnancies, with

1
2
3
4 special reference to the high and increasing incidence of large for gestational age infants (13).
5
6 This study includes a large national cohort of more than 3,000 type 1 diabetic pregnancies and
7
8 the risk of adverse outcome in relation to maternal BMI was also compared with non-diabetic
9
10 pregnancies. Our hypothesis was that maternal overweight/obesity and maternal type 1
11
12 diabetes have independent impact on the risk of adverse outcome and that the combination of
13
14 the two constitutes the greatest risk.
15
16
17
18
19

20 **Research design, material and methods**

21
22 This population based cohort study was based on data from the Swedish Medical Birth
23
24 Registry (MBR). The MBR prospectively collects information on maternal medical history,
25
26 obstetric and neonatal diagnoses and covers more than 99% of all pregnancies in Sweden.
27
28 Until 2008, the MBR did only collect data on pregnancies from 28^{0/7} weeks of gestation and
29
30 did not register data on earlier fetal losses or induced abortions. The quality of data in the
31
32 registry is continuously evaluated by the National Board of Health and the conclusion of the
33
34 latest extensive validation in 2002 was that quality of data is high (18). Maternal and neonatal
35
36 diagnoses were classified according to ICD-10, introduced in Sweden in 1997. ICD 9 codes
37
38 were also included to ensure that no patients would be missed. All diagnoses were made by a
39
40 physician before hospital discharge and copies of the records were forwarded to the MBR.
41
42 Maternal characteristics included in the present study were mother's age, parity, pre-
43
44 pregnancy weight, height, chronic hypertension, smoking habits, and whether the mother was
45
46 born in one of the Nordic countries (Sweden, Finland, Denmark, Norway or Iceland) or
47
48 elsewhere. Chronic hypertensive disease ICD-10: I10 or O10.0) was defined as blood pressure
49
50 above 140/90 mmHg diagnosed before pregnancy or before 20 weeks of gestation. Maternal
51
52 height and pre-pregnancy weight were recorded by recall and body mass index (BMI) was
53
54 calculated as weight in kg divided by the square of the height in meters. Exposure in women
55
56
57
58
59
60

with and without T1DM was defined as overweight (BMI \geq 25-29.9 kg/m²) or obese (BMI \geq 30 kg/m²) and pregnancy outcomes were compared with that of normal weight women (BMI 18.5-24.9 kg/m²). Women with BMI $<$ 18.5 kg/m² (under-weight) and records with missing data on BMI were excluded as well as records with extreme values on maternal age ($<$ 13 or $>$ 54 years) maternal weight ($<$ 40 or $>$ 200 kg) or maternal height ($<$ 120 or $>$ 200 cm). We applied the same limits for data acceptance of birth weight and birth length as in the National Perinatal Quality Registry in Sweden: i.e., records with birth weight $<$ 200 or $>$ 9998 grams or birth length $<$ 15 or $>$ 65 cm, were excluded.

Study cohort

Infants from singleton pregnancies and born to mothers with type 1 diabetes in Sweden between 1998 and 2007 were included, in total n=3,457. Type 1 diabetic pregnancies were identified based on ICD10 code O240 and ICD 9 code 250 for pre-gestational diabetes.

Non-diabetic cohort

The reference group (n= 764,498) included all singleton pregnancies to mothers without a diagnosis of diabetes [based on ICD 10 and 9 codes for type 1 diabetes (O240, 250x1/x3), type 2 diabetes (O241) and all codes starting with E11 and E 177-119,250x0/x2 or gestational diabetes codes (O244 A, B, X, 648.8)] and born in the same time period as the study cohort. Percentiles for birth weight were based on all live born, singleton infants, without major malformations, to mothers without a diagnosis of diabetes. Birth weight percentiles were adjusted for sex and gestational age.

Primary outcome

1
2
3
4 Fetal macrosomia, i.e. giving birth to a large for gestational age (LGA) infant was the primary
5
6 outcome of this study. LGA was defined as a birth weight >90th percentile for sex and
7
8 gestational age.
9

10 11 12 13 *Secondary outcomes*

14
15 Secondary outcomes were major malformations, preeclampsia, preterm delivery, perinatal
16
17 mortality, delivery by Caesarean section (emergency and elective) and neonatal overweight.
18
19 Major malformations were pre-defined in the MBR as fatal or potentially life threatening
20
21 malformations or if the malformation would likely lead to a serious handicap or major
22
23 cosmetic defect if not surgically corrected. Preeclampsia was defined as a blood pressure
24
25 above 140/90 mmHg after 20 weeks of gestation and proteinuria (at least 0.3 g/day or > 1+ on
26
27 a urine dipstick, ICD-10 codes: O14.0, O14.1 and O15/ICD 9 codes: 642.4, 642.5 and 642.6).
28
29 Preterm birth was defined as delivery before 37 gestational weeks. Perinatal mortality was
30
31 defined as intrauterine death after 28^{0/7} weeks of gestation or death during the first week of
32
33 postnatal life. Neonatal overweight was defined as birth weight and ponderal index (PI: birth
34
35 weight in grams/length cm)³ above the 90th percentile for sex and gestational age.
36
37
38
39
40
41

42 This study was approved by the Regional Ethical Review Board in Uppsala, Sweden.
43
44
45

46 47 *Statistical methods*

48
49 Comparison between groups were made using Kruskal Wallis test for continuous data and χ^2
50
51 test and χ^2 test for trend for binary and categorical data as appropriate. Unconditional logistic
52
53 regression was used to explore associations between maternal BMI categories and adverse
54
55 outcomes with normal weight (BMI 18.5-24.9 kg/m²) women as the reference category as
56
57 follows: the odds ratios of adverse outcomes in relation to BMI category were estimated in
58
59
60

1
2
3
4 women with type 1 diabetes with 1) normal weight women with type 1 diabetes as reference
5 category and 2) with normal weight non-diabetic women as reference category. Crude and
6
7
8 adjusted odds ratios (OR) were calculated. The following variables were included in the final
9
10 regression model for LGA as possible confounders because of their established association
11
12 with the primary outcome: Nordic origin (yes/no), maternal age, height, parity, smoking and
13
14 chronic hypertension. The final regression models for the secondary outcomes included
15
16 covariates significantly associated with the outcomes in univariate analysis. Missing indicator
17
18 variables were used for maternal age and height. The likelihood ratio test was used to
19
20 explore potential interaction between BMI categories and T1DM for the risk of the adverse
21
22 outcomes. A p-value <0.05 was considered significant. All statistical analyses were performed
23
24 using STATA 10.1 SE.
25
26
27
28
29
30

31 **Results**

32
33 Between 1998 and 2007, there were 947,096 deliveries in Sweden, including 4,208 (0.4%)
34
35 deliveries to mothers with type 1 diabetes. Of all pregnancies, we excluded 441 records
36
37 (0.05%) with extreme values on maternal age, maternal weight or height. No records were
38
39 excluded due to extreme values on birth weight but 3,402 records were missing for this
40
41 variable. We excluded 90 records (0.01%) due to extreme values on birth length and 14,544
42
43 were missing for birth length. In women with type 1 diabetes, 652 records (15%) were
44
45 excluded due to missing data on maternal BMI or BMI<18.5 and 116 (2.8%) due to multiple
46
47 pregnancies. 17 records were identified as both missing for BMI and with multiple
48
49 pregnancies, thus giving a final study cohort of 3,457 infants (1,758 male infants, 51%) born
50
51 to mothers with type 1 diabetes. The reference population included 764,498 singleton
52
53 pregnancies to mothers without a diagnosis of diabetes, excluding 28,018 records from
54
55 multiple pregnancies and 147,835 records with missing data on maternal BMI or BMI<18.5.
56
57
58
59
60

1
2
3
4 Reference percentiles for birth weight, birth length and ponderal index were formed using
5 records from all non-diabetic pregnancies and excluding stillborn infants (0.31%), infants
6 with major malformations (1.84%) and multiple pregnancies (3.01%).
7
8
9

10 11 12 13 *Maternal and infant characteristics* 14

15 Mothers with type 1 diabetes had a significantly higher median pre-pregnancy BMI (25.1
16 kg/m²) compared to the non-diabetic group (23.6 kg/m², p<0.001). In the type 1 diabetic
17 cohort, 35% (n= 1,195) of women were overweight and 18% (n=618) were obese as
18 compared with 26% (n=200,600) and 11% (n=82,331), respectively, in the non-diabetic
19 population. Women with type 1 diabetes were also more often of Nordic origin, had a higher
20 prevalence of chronic hypertension and smoking during the first trimester compared to
21 women without diabetes (p-value for all comparisons <0.01). Infants to mothers with diabetes
22 type 1 were born at a significantly lower median gestational age and preterm birth was four
23 times as common compared to non-diabetic offspring (p-value for all comparisons <0.001).
24 The median birth weight was significantly higher in infants delivered by mothers with type 1
25 diabetes than in the reference group, Table 1.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1) Maternal and infant characteristics, type 1 diabetes and non-diabetic reference population

	Type 1 diabetes N=3,457	Non-diabetic population N=764,498	P-value
Maternal characteristics			
Nordic, n (%)	3,194 (92)	643,608 (84)	<0.001
Swedish origin, n (%)	3,151 (91)	628,534 (82)	<0.001
Maternal age, years (median, IQR)	30 (27-34)	30(27-33)	<0.001
Smoking first trimester, n (%)	384 (11)	72,766 (10)	0.001
Primipara, n (%)	1,559 (45)	337,199 (44)	0.242
BMI, kg/m ² (median, IQR)	25.1 (23.0-28.4)	23.6 (21.6-26.4)	<0.001
Over weight (BMI ≥ 25-29.9), n_(%)	1,195 (35%)	200,600 (26%)	<0.001
Obese (BMI ≥30), n_(%)	618 (18%)	82,331 (11%)	<0.001
Height, cm (median,IQR)	167 (162-170)	167 (162-170)	0.250
Chronic hypertension, n (%)	92 (2.7)	2,472 (0.32)	<0.001
Infant characteristics			
Male, n (%)	1,758 (51%)	393,324 (51%)	0.485
Gestational age, weeks (md,IQR)	38 (37-39)	40 (39-41)	<0.001
Preterm delivery n (%)	741 (21%)	35,878 (4.7%)	<0.001
Birth weight, g (md,IQR)	3805 (3350-4265)	3575 (3240-3915)	<0.001
Birth length, cm (md,IQR)	51 (49-52)	51 (49-52)	0.576
LGA, BW >90 percentile, n (%)	1,694 (49)	81,142 (11)	<0.001
AGA, BW 10-90 percentile, n (%)	1,661 (48%)	614,784 (80%)	<0.001
SGA, BW <10 percentile, n (%)	109 (3.2%)	76,214 (10)	<0.001

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Adverse outcomes in relation to body mass index category (Table 2)

Overall, the incidence of all adverse outcomes was significantly higher in women with type 1 diabetes, irrespective of BMI category. The incidence of the primary outcome LGA was highest in obese T1DM women; however the differences between BMI categories did not reach statistical significance within the diabetes cohort. The incidence of all secondary outcomes was highest in obese women with type 1 diabetes, except for PMR in type 1 diabetic pregnancies with the highest recorded frequency in overweight women. Within the non-diabetic pregnancies, the incidence of all outcomes increased significantly with greater BMI category (chi square test for trends for all outcomes $p < 0.001$), Table 2.

Table 2) Perinatal outcomes for pregnant women with or without type 1 diabetes and stratified on pre-pregnancy BMI. Data are presented as numbers (percentages).

	BMI 18.5-24.9	BMI 25-29.9	BMI≥30	P-value
LGA-infant				
Type 1 diabetes	778 (47)	603 (50)	313 (51)	0.170
Non-diabetic	39,265 (8.2)	26,828 (13)	15,049 (18)	<0.001
Major malformations				
Type 1 diabetes	65 (4.0)	44 (3.7)	41 (6.6)	0.008
Non-diabetic	8,186 (1.7)	3,736 (1.9)	1,610 (2.0)	<0.001
Preeclampsia				
Type 1 diabetes	222 (14)	185 (15)	114 (18)	0.012
Non-diabetic	9,872 (2.1)	6,529 (3.3)	4,810 (5.8)	<0.001
Preterm delivery				
Type 1 diabetes	322 (20)	275 (23)	144 (23)	0.041
Non-diabetic	21,714 (4.5)	9,464 (4.7)	4,700 (5.7)	<0.001
Perinatal mortality				
Type 1 diabetes	14 (0.85)	15 (1.3)	6 (0.97)	0.566
Non-diabetic	1,554 (0.32)	948 (0.47)	593 (0.72)	<0.001
Caesarean section				
Type 1 diabetes	748 (46)	639 (53)	362 (59)	<0.001
Non-diabetic	64,131 (13)	34,081 (17)	18,166 (22)	<0.001
Neonatal overweight				
Type 1 diabetes	351 (21)	288 (24)	166 (27)	0.016
Non-diabetic	15,359 (3)	10,430 (5)	6,466 (8)	<0.001

*Chi square test, Kruskal Wallis test, Chi square test for trends

1
2
3
4
5
6
7 There was a similar pattern of increasing odds ratio for adverse outcome with greater BMI
8 category in women with and without type 1 diabetes. Inclusion of maternal covariates in the
9 regression models did not significantly change these estimates. Relative to a normal weight
10 non-diabetic woman, the adjusted OR for the risk of having a LGA infant in overweight or
11 obese women with type 1 diabetes was approximately 13, as compared with approximately 2
12 in overweight and obese non-diabetic women, Table 3. In relation to a normal weight woman
13 without diabetes, obesity in women with type 1 diabetes was associated with an adjusted OR
14 for major malformation of 4.11 (2.99-5.65) as compared with 1.15 (1.09-1.22) in non-diabetic
15 women with obesity. Compared with a normal weight non-diabetic woman, the adjusted odds
16 ratios for PE in a woman with type 1 diabetes of normal weight was 7.17 (6.04-8.50) and in
17 combination with overweight 9.91 (8.61-11.40) and in obese T1DM women the adjusted OR
18 was 14.19 (11.50-17.50). The corresponding estimates for a non-diabetic woman with
19 overweight or obesity were 1.74(1.69-1.80) and 3.37 (3.25-3.49), respectively. The OR for
20 Caesarean section increased with BMI category, both in women with and without type 1
21 diabetes, Table 3.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3) Crude and adjusted* odds ratios (OR; 95%CI) for adverse perinatal outcomes in pregnant women with and without type 1 diabetes (T1DM) and stratified on pre-pregnancy BMI. Reference group: non-diabetic women with normal pre-pregnancy BMI.

		BMI 18.5-24.9	BMI 25-29.9	BMI≥30	Interaction# P-value
LGA-infant	T1DM; Crude	10.16 (9.10-11.36)	12.40 (11.22-13.70)	12.29 (10.50-14.40)	<0.001
	Adjusted	10.72 (9.56-12.01)	13.55 (12.23-15.02)	13.26 (11.27-15.59)	<0.001
Non-diabetic ;	Crude	1.0	1.74 (1.71-1.77)	2.52 (2.47-2.57)	<0.001
	Adjusted	1.0	1.76 (1.73-1.79)	2.60 (2.55-2.66)	<0.001
Major malformations	T1DM; Crude	2.28 (1.71-3.04)	2.34 (1.81-3.02)	4.11 (2.99-5.65)	0.03
	Adjusted	2.28 (1.71-3.04)	2.34 (1.81-3.03)	4.11 (2.99-5.65)	0.03
Non-diabetic; Crude	Crude	1.0	1.10 (1.06-1.14)	1.15 (1.09-1.22)	0.03
	Adjusted	1.0	1.10 (1.06-1.14)	1.15 (1.09-1.22)	0.03
Preeclampsia	T1DM; Crude	7.12 (6.02-8.42)	9.30 (8.11-10.67)	11.23 (9.15-13.77)	<0.001
	Adjusted	7.17 (6.04-8.50)	9.91(8.61-11.40)	14.19 (11.50-17.50)	<0.001
Non-diabetic; Crude	Crude	1.0	1.61(1.56-1.66)	2.96 (2.86-3.07)	<0.001
	Adjusted	1.0	1.74 (1.69-1.80)	3.37 (3.25-3.49)	<0.001
Preterm delivery	T1DM; Crude	4.86 (4.22-5.60)	6.23 (5.53-7.02)	6.39 (5.30-7.71)	0.16
	Adjusted	4.72 (4.09-5.44)	5.98 (5.31-6.74)	5.97 (4.94-7.21)	0.15
Non-diabetic; Crude	Crude	1.0	1.05 (1.02-1.07)	1.28 (1.24-1.32)	0.16
	Adjusted	1.0	1.04 (1.02-1.07)	1.26 (1.22-1.30)	0.15

Perinatal mortality					
T1DM;	Crude	2.55 (1.36-4.76)	3.93 (2.49-6.19)	3.14 (1.40-7.04)	0.29
	Adjusted	2.46 (1.32-4.60)	3.72 (2.36-5.89)	2.86 (1.27-6.44)	0.31
Non-diabetic ; Crude		1.0	1.47 (1.35-1.59)	2.24 (2.04-2.46)	0.29
Adjusted		1.0	1.46 (1.35-1.59)	2.22 (2.03-2.44)	0.31
Caesarean section					
T1DM;	Crude	5.59 (5.00-6.25)	7.09 (6.42-7.83)	9.44 (8.04-11.08)	0.42
	Adjusted	5.69 (5.09-6.37)	7.12 (6.44-7.88)	9.35 (7.95-11.00)	0.36
Non-diabetic; Crude		1.0	1.33 (1.31-1.35)	1.84 (1.81-1.88)	0.42
Adjusted		1.0	1.34 (1.32-1.36)	1.87 (1.83-1.90)	0.36
Neonatal overweight					
T1DM;	Crude	8.46 (7.39-9.70)	9.93 (8.83-11.17)	11.71 (9.79-14.00)	<0.001
	Adjusted	8.40 (7.32-9.64)	9.86 (8.76-11.11)	11.29 (9.42-13.53)	<0.001
Non-diabetic; Crude		1.0	1.66 (1.62-1.71)	2.59 (2.51-2.67)	<0.001
Adjusted		1.0	1.65 (1.61-1.69)	2.55 (2.48-2.63)	<0.001

*Adjusted for ethnicity, maternal age, height, parity, smoking first trimester, chronic hypertension

#Interaction between BMI category and T1DM

Table 4 shows the OR for adverse outcome in women with type 1 diabetes by BMI category with normal weight women with type 1 diabetes as the reference category. In obese T1DM women the adjusted OR of major malformations [1.77 (1.18-2.65)] and preeclampsia [1.74(1.35-2.25)] were significantly increased compared with normal weight T1DM women. The OR of Caesarean section was significantly increased in both overweight and obese T1DM women, Table 4. The OR for LGA did not differ significantly between the different

1
2
3
4 BMI categories. However, the adjusted OR for delivering a disproportionate LGA-infant with
5
6 neonatal overweight (ponderal index >90th percentile) was significantly increased in obese
7
8
9 T1DM women 1.36 (1.09-1.69).
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 4) Crude and Adjusted* Odds ratios (OR; 96%CI) for adverse perinatal outcome in pregnant women with type 1 diabetes (T1DM) and stratified on BMI. Reference group: T1DM women with normal pre-pregnancy BMI.

	T1DM BMI 18.5-24.9	T1DM BMI 25-29.9	T1DM BMI≥30
LGA-infant			
Crude	1.0	1.13 (0.98-1.32)	1.14 (0.95-1.37)
Adjusted	1.0	1.18 (1.01-1.38)	1.21 (1.00-1.47)
Major malformations			
Crude	1.0	0.93 (0.63-1.37)	1.73 (1.15-2.58)
Adjusted	1.0	0.92 (0.62-1.36)	1.77 (1.18-2.65)
Preeclampsia			
Crude	1.0	1.17 (0.95-1.45)	1.45 (1.13-1.86)
Adjusted	1.0	1.21 (0.98-1.50)	1.74 (1.35-2.25)
Preterm delivery			
Crude	1.0	1.23 (1.02-1.47)	1.25 (1.00-1.56)
Adjusted	1.0	1.22 (1.02-1.47)	1.25 (1.00-1.56)
Perinatal mortality			
Crude	1.0	1.48 (0.71-3.08)	1.14 (0.44-2.98)
Adjusted	1.0	1.47 (0.70-3.03)	1.08 (0.41-2.83)
Caesarean section			
Crude	1.0	1.38 (1.19-1.60)	1.69 (1.40-2.04)
Adjusted	1.0	1.37 (1.18-1.60)	1.67 (1.38-2.03)
Neonatal overweight			
Crude	1.0	1.17 (0.98-1.40)	1.35 (1.09-1.67)
Adjusted	1.0	1.19 (0.99-1.42)	1.36 (1.09-1.69)

*Adjusted for ethnicity, maternal age, height, parity, smoking first trimester, chronic hypertension

Discussion

This study shows that high maternal pre-pregnancy BMI is a very important risk factor for adverse pregnancy outcome in women with and without type 1 diabetes. High maternal BMI and type 1 diabetes are independent risk factors for maternal and perinatal complications. However, type 1 diabetes remains a stronger risk factor for adverse outcome than obesity. The risk of adverse outcome in women with concomitant type 1 diabetes and obesity exceeds that of either condition alone, indicating synergism between the two exposures. Obesity in type 1 diabetes is associated with significantly increased risk of PE, major malformations and Caesarean section as compared with type 1 diabetic women with normal BMI.

The prevalence of overweight and obesity in pregnant women is increasing in Sweden and worldwide (1, 12) and the harmful effects of high maternal BMI on pregnancy outcome are well established in the general obstetric population (2-11). On the other hand, data on the potential association between high maternal BMI and adverse pregnancy outcome in women with type 1 diabetes is scarce (17, 19-20). In a cohort of 46 women with type 1 diabetes and nephropathy, maternal overweight was identified as an important risk factor for poor pregnancy outcome (19). In mixed populations of women with pre-gestational diabetes, maternal obesity has been associated with pregnancy complications (20) and increased risk of birth defects (17). These two studies however, do not separate women with diabetes type 1 from those with diabetes type 2 and do not include any comparable data from a non-diabetic reference population.

The present study is to our knowledge, the first to present risk estimates of obstetric and perinatal complications in a large cohort of women with exclusively type 1 diabetes, stratified by BMI category and compared with a non-diabetic reference population. The large sample

1
2
3
4 size enabled risk estimation of rare outcomes such as perinatal mortality and major
5
6 malformations in relation to subgroups of maternal BMI. The population based study design
7
8 provides unanimous risk estimates for overweight and obese women with and without type 1
9
10 diabetes. The vast majority of our study population is of Nordic origin and 91% were
11
12 Swedish. The study population is also homogenous with respect to medical care in pregnancy.
13
14 In Sweden, healthcare is free of charge as well as insulin, test strips for home monitoring of
15
16 glucose and equipment for insulin administration. The care of pregnant women with type 1
17
18 diabetes is uniform over the whole country and pregnancy outcome does not differ with
19
20 geographical area (13).
21
22
23
24

25
26 Some limitations with the present study should be noted. Body mass index was calculated
27
28 from recalled data on pre-pregnancy weight and height. Women tend to underestimate their
29
30 weight and it has been demonstrated that this bias increases directly with the degree of
31
32 overweight (21). A potential misclassification of women to lower BMI categories would lead
33
34 to an underestimation of our findings of increased risks associated with high maternal BMI.
35
36 The Swedish MBR does not collect data on maternal glycaemic control, duration of diabetes,
37
38 insulin regimens nor data on diet and physical activity. Data on socioeconomic factors is also
39
40 very limited. Consequently, the impact of socioeconomic factors, diet, physical activity and
41
42 level of control on the risk of adverse outcome could not be assessed. It is plausible that the
43
44 achieved level of metabolic control differed between normal weight, overweight and obese
45
46 type 1 diabetic women. In a study on pregnancies complicated by gestational diabetes, the
47
48 fasting glucose levels were significantly higher in obese compared with overweight and
49
50 normal weight women (14). However, results from the HAPO study confirm that maternal
51
52 BMI and glycaemia exert independent effects on the risk of adverse pregnancy outcome (2).
53
54
55
56
57
58
59
60

1
2
3
4 In the present study, obese women with type 1 diabetes had significantly increased risks of
5 major malformations and preeclampsia as compared with normal weight women with type 1
6 diabetes. This is in line with the finding of an interaction between maternal diabetes and
7 obesity on the risk of adverse outcome in a mixed population of women with different types
8 of diabetes (17). However, the increased risk of major malformations in relation to BMI in the
9 present analysis should be interpreted with caution as maternal overweight and obesity rend
10 ultrasound assessment of fetal anatomy difficult (22) and we do not have data on the number
11 of induced abortions due to malformations. Maternal hyperglycaemia in early pregnancy is a
12 well known risk factor for major malformations and preeclampsia (23). Obesity is associated
13 with increased insulin resistance (12) and one could speculate that women with obesity had a
14 poorer level of control in early pregnancy than women with normal or slightly elevated BMI.
15
16 In line with previous studies, we found increased risks of PE and major malformations in
17 obese non diabetic women (5, 6, 10). In the present study, the risks of these complications
18 were also significantly elevated in non- diabetic women with overweight. Obesity is
19 associated with decreased insulin sensitivity and already slightly elevated levels of fasting
20 glucose, within the upper normal range, are associated with increased risk of preeclampsia in
21 women without diabetes (24). In Sweden, there is no uniform screening for gestational
22 diabetes. It is possible that the increased risk of PE and major malformations in overweight
23 and obese women in the reference group is partly due to undetected cases of impaired glucose
24 tolerance or diabetes. Interestingly, maternal pre-pregnancy BMI has been demonstrated as a
25 stronger predictor of major malformations than severity of gestational diabetes (25).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51
52
53 In women with type 1 diabetes, the incidence of LGA was very high in all weight classes and
54 increased with greater BMI category. However, the odds ratio for an LGA outcome did not
55 differ significantly between BMI categories, as opposed to in non-diabetic women. This is in
56
57
58
59
60

1
2
3
4 | accordance with findings in two recent studies (26, 27). On the contrary, the risk of delivering
5 a disproportionate, overweight LGA infant (PI > 90th percentile) was significantly increased
6
7 in obese women within the type 1 diabetic cohort. In accordance with the study by Ehrenberg
8
9 our findings indicate that maternal overweight is an important risk factor for LGA, but
10
11 maternal diabetes has an even greater impact (28). A possible contributing factor to this
12
13 finding could also be the increasing prevalence of preeclampsia with greater BMI category.
14
15
16
17
18
19

20 This study confirms the observations in non-diabetic pregnancies (2-5) that increasing
21
22 maternal BMI is associated with increased risk of delivery by Caesarean section also in
23
24 women with type 1 diabetes. The increased incidence of complications such as preeclampsia
25
26 and LGA in these groups most likely contributes to this finding.
27
28
29
30

31 The majority of perinatal deaths were stillbirths in all BMI categories and in both women with
32
33 and without type 1 diabetes. The risk of perinatal mortality was independent of BMI category
34
35 within the type 1 diabetic cohort but increased significantly with higher BMI in the reference
36
37 group. This finding is in line with previous studies, reporting increased risk of both stillbirth
38
39 and neonatal mortality in obese, non-diabetic women even after adjusting for maternal and
40
41 perinatal risk factors (7, 8, 9). The lack of a significantly increased risk of perinatal mortality
42
43 with increasing BMI category within the diabetes cohort, indicate that diabetes is a stronger
44
45 risk factor for perinatal mortality than maternal overweight/obesity.
46
47
48
49
50

51 In the present study, we found an increasing risk of preterm delivery with greater BMI
52
53 category, both in women with and without type 1 diabetes. Results from some earlier studies
54
55 have shown an increased risk of preterm delivery in obese non-diabetic women (3, 4) while
56
57 others have reported the opposite association (2, 5).
58
59
60

1
2
3
4
5
6
7 It is hypothesized that the increased risk of pregnancy complications in overweight and obese
8
9 women is related to increased maternal fat mass. In the present study, pre-pregnancy BMI
10
11 was used as a proxy for maternal fat mass as there is a strong correlation ($r^2= 0.86$) between
12
13 pre-pregnancy BMI and maternal fat mass in women without diabetes (29). However, BMI
14
15 does not provide information on the localization of fat mass. One suggested link between high
16
17 maternal pre-pregnancy BMI and increased risk of adverse outcome pregnancy is a large
18
19 visceral fat mass. The visceral fat mass is associated with increased insulin resistance,
20
21 inflammation and lipotoxicity with potential harmful effects on maternal vascular and
22
23 placental function and fetal development (30). Other pathophysiological mechanisms behind
24
25 the increased risk of adverse pregnancy outcome in overweight/obese mothers are not clear
26
27 but are most likely complex. Genetic- and socioeconomic factors, maternal diet and physical
28
29 activity are probable contributing factors.
30
31
32
33
34
35

36 In conclusion, this population based study on more than 3000 type 1 diabetic pregnancies
37
38 demonstrates a strong association between maternal pre-pregnancy BMI and elevated risk of
39
40 adverse pregnancy outcome. Type 1 diabetes in combination with overweight or obesity
41
42 constitutes a higher risk than either condition alone. Striving towards normal pre-pregnancy
43
44 BMI in women with type 1 diabetes could hopefully reduce the risk of adverse outcome.
45
46
47
48

49 **Acknowledgement**

50
51 This study was supported by the Swedish Order of Freemasons and the Stockholm County
52
53 Council. DP was funded by the National Institute of Health Research (NIHR), UK and the
54
55 Tommy's Charity. The funding consisted of salary for the researchers MP and DP. We
56
57 appreciate the help from the Swedish Medical Birth Registry to provide us with data.
58
59
60

Disclosure of interest

The authors have no potential conflicts of interest.

Author contributions

MP. DP.UH.MW.MN; contributions of design and interpretation of data

MP. UH; Data acquisition

MP. DP; Data analyses

MP. DP.UH.MW. MN; Interpretation of results

MP. MN; Drafted the manuscript

MN; Handled funding and supervision

MP. DP. UH. MW.MN; Critical revision of the manuscript and final approval of the version to be published

Ethics Approval

This study was approved by the Regional Ethical Review Board in Uppsala, Sweden. Date of approval: 22/7 2009, reference number: 2009/187

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Data sharing statement

No additional data available.

.

References:

- 1) Surkan P, Chung-Cheng Hsieh, Johansson A.L.V et al.Reasons for Increasing Trends in Large for Gestational Age Births *Obstetrics and Gynecology* 2004;104:4
- 2) HAPO Study Cooperative Research Group. Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) Study: associations with maternal body mass index. *BJOG*;2010;117:575-584
- 3) Callaway L.K, Prins J.B, Chang A.M et al.The prevalence and impact of overweight and obesity in an Australian obstetric population. *MJA*;2006;2:56-59
- 4) Heslehurst N, Simpson H, Ells L.J et al.The impact of maternal BMI status on pregnancy outcomes with immediate short-term obstetric resource implications:a meta-analysis. *Obesity Reviews*;2008;9:635-683
- 5) Athukorala C, Rumbold A.R, Willson K.J et al.The risk of adverse pregnancy outcomes in women who are overweight or obese. *BMC Pregnancy and Childbirth*;2010;10:56
- 6) Stothard K.J, Tennant P.W.G, Bell R et al. Maternal Overweight and Obesity and the Risk of Congenital Anomalies. A systematic Review and Meta-analysis. *JAMA*;2009;301:636-650
- 7) Kristensen J, Vestergaard M, Wisborg K et al.Pre-pregnancy weight and the risk of stillbirth and neonatal death. *BJOG*;2005;112:403-408
- 8) Nohr E.A, Vaeth M, Bech B.H et al.Maternal Obesity and Neonatal Mortality According to Subtypes of Preterm Birth. *Obstet Gynecol*;2007;110:1083-1090
- 9) Cnattingius S, Bergström R, Lipworth L et al. Prepregnancy weight and the risk of adverse pregnancy outcomes. *N Engl J Med* ;1998;338:147-152.
- 10) O'Brien TE, Ray JG, Chan WS. Maternal body mass index and the risk of preeclampsia: a systematic overview. *Epidemiology*;2003;14:368-374

- 1
2
3
4
5 11) Chen A, Feresu S.A, Fernandez C et al. Maternal Obesity and the Risk of Infant Death in
6
7 the United States. *Epidemiology*;2009;20:74-81
8
9
10 12) Catalano P. Obesity, insulin resistance, and pregnancy outcome.
11
12 *Reproduction*;2010;140:365-371
13
14 13) Persson M, Norman M, Hanson U. Obstetric and perinatal outcomes in type 1 diabetic
15
16 pregnancies - a large, population-based study. *Diabetes Care* 2009;32:2005-9
17
18 14) Roman AS, Rebarber A, Fox N.S et al. The effect of maternal obesity on pregnancy
19
20 outcomes in women with gestational diabetes.
21
22 *J Matern Fetal Neonatal Med*;2011;24(5):723-727
23
24 15) Yogev Y, Langer O. Pregnancy outcome in obese and morbidly obese gestational diabetic
25
26 women. *European Journal of Obstetrics and Gynecology and Reproductive*
27
28 *Biology*;2008;137:21-26
29
30 16) Langer O, Yogev Y, Xenakis E.M.J et al. Overweight and obese in gestational
31
32 diabetes: The impact on pregnancy outcome. *Am J Obstet Gynecol*;2005;192:1768-1776
33
34 17) Moore L.L, Singer M.R, Bradlee M.L et al. A prospective study of the risk of congenital
35
36 defects associated with maternal obesity and diabetes mellitus.
37
38 *Epidemiology*;2000;11:689-694
39
40 18) The National Board of Health and Welfare (Socialstyrelsen) [Internet]. Available from
41
42 <http://www.sos.se/epc/fodelse/mfr.htm>. Accessed December 18, 2012.
43
44
45
46 19) Yogev Y, Chen R, Ben-Haroush A et al. Maternal overweight and pregnancy outcome in
47
48 women with type 1 diabetes mellitus and different degrees of nephropathy. *The J of*
49
50 *Maternal-Fetal and Neonatal Medicine*;2010;23:999-1003
51
52 20) Ray J.G, Vermeulen M.J, Shapiro J.L et al. Maternal and neonatal outcomes in
53
54 pregestational and gestational diabetes mellitus, and the influence of maternal obesity and
55
56 weight gain: the DEPOSIT study. *Q J Med*;2001;94:347-356
57
58
59
60

- 1
2
3
4 21) Rowland ML. Self-reported weight and height. *Am J Clin Nutr*;1990:52(6):1125-1133
5
6 22) Dashe JS, McIntire DD, Twickler DM. Maternal obesity limits the ultrasound evaluation
7
8 of fetal anatomy. *J Ultrasound Med*;2009:28(8):1025-1030
9
10 23) Taylor R, Davidson J.M. Type 1 diabetes and pregnancy. *BMJ*;2007:334:742-5
11
12 24) The HAPO study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy
13
14 Outcomes. *N Eng J of Medicine*;2008:358:1991
15
16 25) Garcia-Patterson A, Erdozain L, Ginovart G et al. In human gestational diabetes mellitus
17
18 congenital malformations are related to pre-pregnancy body mass index and to severity of
19
20 diabetes. *Diabetologia*; 2004;47:509-514
21
22 26) Murphy H.R, Steel S.A, Roland J.M et al. Obstetric and perinatal outcomes in pregnancies
23
24 complicated by Type 1 and Type 2 diabetes:influences of glycaemic control,obesity and
25
26 social disadvantage. *Diabetic Medicin*;2011:28:1060-1067
27
28 27) Feghali M, Khoury J.C, Timofeev J et al. Asymmetric Large For Gestational Age in
29
30 Newborns in Pregnancies Complicated by Diabetes Mellitus:Is Maternal Obesity a
31
32 Culprit? *J Matern Fetal Neonatal Med*;2011 30 sep [Epub ahead of print]
33
34 28) Ehrenberg H.M, Brian M.M, Catalano P. The influence of obesity and diabetes on the
35
36 prevalence of macrosomia. *Am J Obstet Gynecol*;2004:191:964-968
37
38 29) Sewell MF, Huston-Presley L, Amini SB et al.Body mass index: a true indicator of body
39
40 fat in obese gravidas. *J Reprod Med*;2007:52(10):907-11
41
42 30) Jarvie E, Hauguel-de-Mouzon S, Nelson S, Sattar N, Catalano P, Freeman D J.
43
44 Lipotoxicity in obese pregnancy and its potential role in adverse pregnancy outcome and
45
46 obesity in the offspring. *Clinical Science*;2010:119:123-12
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1) Maternal and infant characteristics, type 1 diabetes and non-diabetic reference population

	Type 1 diabetes N=3,457	Non-diabetic population N=764,498	P-value
Maternal characteristics			
Nordic, n (%)	3,194 (92)	643,608 (84)	<0.001
Swedish origin, n (%)	3,151 (91)	628,534 (82)	<0.001
Maternal age, years (median, IQR)	30 (27-34)	30(27-33)	<0.001
Smoking first trimester, n (%)	384 (11)	72,766 (10)	0.001
Primipara, n (%)	1,559 (45)	337,199 (44)	0.242
BMI, kg/m ² (median, IQR)	25.1 (23.0-28.4)	23.6 (21.6-26.4)	<0.001
Over weight (BMI ≥ 25-29.9), n_(%)	1,195 (35%)	200,600 (26%)	<0.001
Obese (BMI ≥30), n_(%)	618 (18%)	82,331 (11%)	<0.001
Height, cm (median,IQR)	167 (162-170)	167 (162-170)	0.250
Chronic hypertension, n (%)	92 (2.7)	2,472 (0.32)	<0.001
Infant characteristics			
Male, n (%)	1,758 (51%)	393,324 (51%)	0.485
Gestational age, weeks (md,IQR)	38 (37-39)	40 (39-41)	<0.001
Preterm delivery n (%)	741 (21%)	35,878 (4.7%)	<0.001
Birth weight, g (md,IQR)	3805 (3350-4265)	3575 (3240-3915)	<0.001
Birth length, cm (md,IQR)	51 (49-52)	51 (49-52)	0.576
LGA, BW >90 percentile, n (%)	1,694 (49)	81,142 (11)	<0.001
AGA, BW 10-90 percentile, n (%)	1,661 (48%)	614,784 (80%)	<0.001
SGA, BW <10 percentile, n (%)	109 (3.2%)	76,214 (10)	<0.001

Table 2) Perinatal outcomes for pregnant women with or without type 1 diabetes and stratified on pre-pregnancy BMI. Data are presented as numbers (percentages).

	BMI 18.5-24.9	BMI 25-29.9	BMI≥30	P-value
LGA-infant				
Type 1 diabetes	778 (47)	603 (50)	313 (51)	0.170
Non-diabetic	39,265 (8.2)	26,828 (13)	15,049 (18)	<0.001
Major malformations				
Type 1 diabetes	65 (4.0)	44 (3.7)	41 (6.6)	0.008
Non-diabetic	8,186 (1.7)	3,736 (1.9)	1,610 (2.0)	<0.001
Preeclampsia				
Type 1 diabetes	222 (14)	185 (15)	114 (18)	0.012
Non-diabetic	9,872 (2.1)	6,529 (3.3)	4,810 (5.8)	<0.001
Preterm delivery				
Type 1 diabetes	322 (20)	275 (23)	144 (23)	0.041
Non-diabetic	21,714 (4.5)	9,464 (4.7)	4,700 (5.7)	<0.001
Perinatal mortality				
Type 1 diabetes	14 (0.85)	15 (1.3)	6 (0.97)	0.566
Non-diabetic	1,554 (0.32)	948 (0.47)	593 (0.72)	<0.001
Cesarean section				
Type 1 diabetes	748 (46)	639 (53)	362 (59)	<0.001
Non-diabetic	64,131 (13)	34,081 (17)	18,166 (22)	<0.001
Neonatal overweight				
Type 1 diabetes	351 (21)	288 (24)	166 (27)	0.016
Non-diabetic	15,359 (3)	10,430 (5)	6,466 (8)	<0.001

*Chi square test, Kruskal Wallis test, Chi square test for trends

Table 3) Crude and adjusted* odds ratios (OR; 95%CI) for adverse perinatal outcomes in pregnant women with and without type 1 diabetes (T1DM) and stratified on pre-pregnancy BMI. Reference group: non-diabetic women with normal pre-pregnancy BMI.

		BMI 18.5-24.9	BMI 25-29.9	BMI≥30	Interaction# P-value
LGA-infant					
T1DM;	Crude	10.16 (9.10-11.36)	12.40 (11.22-13.70)	12.29 (10.50-14.40)	<0.001
	Adjusted	10.72 (9.56-12.01)	13.55 (12.23-15.02)	13.26 (11.27-15.59)	<0.001
Non-diabetic ;	Crude	1.0	1.74 (1.71-1.77)	2.52 (2.47-2.57)	<0.001
	Adjusted	1.0	1.76 (1.73-1.79)	2.60 (2.55-2.66)	<0.001
Major malformations					
T1DM;	Crude	2.28 (1.71-3.04)	2.34 (1.81-3.02)	4.11 (2.99-5.65)	0.03
	Adjusted	2.28 (1.71-3.04)	2.34 (1.81-3.03)	4.11 (2.99-5.65)	0.03
Non-diabetic;	Crude	1.0	1.10 (1.06-1.14)	1.15 (1.09-1.22)	0.03
	Adjusted	1.0	1.10 (1.06-1.14)	1.15 (1.09-1.22)	0.03
Preeclampsia					
T1DM;	Crude	7.12 (6.02-8.42)	9.30 (8.11-10.67)	11.23 (9.15-13.77)	<0.001
	Adjusted	7.17 (6.04-8.50)	9.91(8.61-11.40)	14.19 (11.50-17.50)	<0.001
Non-diabetic;	Crude	1.0	1.61(1.56-1.66)	2.96 (2.86-3.07)	<0.001
	Adjusted	1.0	1.74 (1.69-1.80)	3.37 (3.25-3.49)	<0.001
Preterm delivery					
T1DM;	Crude	4.86 (4.22-5.60)	6.23 (5.53-7.02)	6.39 (5.30-7.71)	0.16
	Adjusted	4.72 (4.09-5.44)	5.98 (5.31-6.74)	5.97 (4.94-7.21)	0.15
Non-diabetic;	Crude	1.0	1.05 (1.02-1.07)	1.28 (1.24-1.32)	0.16
	Adjusted	1.0	1.04 (1.02-1.07)	1.26 (1.22-1.30)	0.15

Perinatal mortality					
T1DM;	Crude	2.55 (1.36-4.76)	3.93 (2.49-6.19)	3.14 (1.40-7.04)	0.29
	Adjusted	2.46 (1.32-4.60)	3.72 (2.36-5.89)	2.86 (1.27-6.44)	0.31
Non-diabetic ;	Crude	1.0	1.47 (1.35-1.59)	2.24 (2.04-2.46)	0.29
	Adjusted	1.0	1.46 (1.35-1.59)	2.22 (2.03-2.44)	0.31
Cesarean section					
T1DM;	Crude	5.59 (5.00-6.25)	7.09 (6.42-7.83)	9.44 (8.04-11.08)	0.42
	Adjusted	5.69 (5.09-6.37)	7.12 (6.44-7.88)	9.35 (7.95-11.00)	0.36
Non-diabetic;	Crude	1.0	1.33 (1.31-1.35)	1.84 (1.81-1.88)	0.42
	Adjusted	1.0	1.34 (1.32-1.36)	1.87 (1.83-1.90)	0.36
Neonatal overweight					
T1DM;	Crude	8.46 (7.39-9.70)	9.93 (8.83-11.17)	11.71 (9.79-14.00)	<0.001
	Adjusted	8.40 (7.32-9.64)	9.86 (8.76-11.11)	11.29 (9.42-13.53)	<0.001
Non-diabetic;	Crude	1.0	1.66 (1.62-1.71)	2.59 (2.51-2.67)	<0.001
	Adjusted	1.0	1.65 (1.61-1.69)	2.55 (2.48-2.63)	<0.001

*Adjusted for ethnicity, maternal age, height, parity, smoking first trimester, chronic hypertension

#Interaction between BMI category and T1DM

Table 4) Crude and Adjusted* Odds ratios (OR; 96%CI) for adverse perinatal outcome in pregnant women with type 1 diabetes (T1DM) and stratified on BMI. Reference group: T1DM women with normal pre-pregnancy BMI.

	T1DM BMI 18.5-24.9	T1DM BMI 25-29.9	T1DM BMI≥30
LGA-infant			
Crude	1.0	1.13 (0.98-1.32)	1.14 (0.95-1.37)
Adjusted	1.0	1.18 (1.01-1.38)	1.21 (1.00-1.47)
Major malformations			
Crude	1.0	0.93 (0.63-1.37)	1.73 (1.15-2.58)
Adjusted	1.0	0.92 (0.62-1.36)	1.77 (1.18-2.65)
Preeclampsia			
Crude	1.0	1.17 (0.95-1.45)	1.45 (1.13-1.86)
Adjusted	1.0	1.21 (0.98-1.50)	1.74 (1.35-2.25)
Preterm delivery			
Crude	1.0	1.23 (1.02-1.47)	1.25 (1.00-1.56)
Adjusted	1.0	1.22 (1.02-1.47)	1.25 (1.00-1.56)
Perinatal mortality			
Crude	1.0	1.48 (0.71-3.08)	1.14 (0.44-2.98)
Adjusted	1.0	1.47 (0.70-3.03)	1.08 (0.41-2.83)
Cesarean section			
Crude	1.0	1.38 (1.19-1.60)	1.69 (1.40-2.04)
Adjusted	1.0	1.37 (1.18-1.60)	1.67 (1.38-2.03)
Neonatal overweight			
Crude	1.0	1.17 (0.98-1.40)	1.35 (1.09-1.67)
Adjusted	1.0	1.19 (0.99-1.42)	1.36 (1.09-1.69)

*Adjusted for ethnicity, maternal age, height, parity, smoking first trimester, chronic hypertension

PRE-PREGNANCY BODY MASS INDEX AND THE RISK OF ADVERSE OUTCOME IN
TYPE 1 DIABETIC PREGNANCIES-A POPULATION BASED COHORT

Martina Persson MD ¹, Dharmindra Pasupathy MSc PhD ², Ulf Hanson PhD ³, Magnus
Westgren, PhD ¹Mikael Norman, PhD ¹

¹Department of Clinical Science, Intervention and Technology, Karolinska Institute,
Stockholm, Sweden ² Division of Women's Health, NIHR Biomedical Research Centre,
Kings Health's Partners, King's College London, UK ³Department of Woman and Child
Health, Uppsala University, Sweden.

Short running title: Overweight in type 1 diabetic pregnancies

Word count: 3,773 words (abstract 294 words) excluding references, 1 figure and 4 tables

Corresponding author:

Martina Persson

Address: Sachs' Children's Hospital

S-118 83 Stockholm, Sweden

Telephone number: +46 8-73 980 5959

Fax number: + 46 8-7169564

Email: Martina.Persson@ki.se

Article summary**Article focus**

To assess the risk of obstetric and perinatal complications in overweight and obese women with and without type 1 diabetes (T1DM).

Key findings

- High pre-pregnancy BMI is an important risk factor for adverse outcome in type 1 diabetic pregnancies.
- The combined effect of both type 1 diabetes and overweight or obesity constitutes the greatest risk.
- T1DM is a significant effect modifier of the association between BMI and LGA, major malformations and preeclampsia ($p < 0.001$).

Strengths and Limitations

The present study is to our knowledge, the first to present risk estimates of several obstetric and perinatal complications in women with type 1 diabetes, stratified by BMI category and compared with a non-diabetic reference population. The population based study design, including a very large cohort of T1DM pregnancies offers a unique possibility to provide solid data on risks associated with high BMI, including comparatively rare outcomes such as perinatal mortality. A potential limitation is that the study design did not allow assessment of the impact of maternal glycaemic control on the association between exposure and outcome.

ABSTRACT

Objective To assess the risk of perinatal complications in overweight and obese women with and without type 1 diabetes (T1DM).

Design Prospective population-based cohort study.

Setting This study was based on data from the Swedish Medical Birth Registry from 1998 - 2007.

Participants 3,457 T1DM and 764,498 non-diabetic pregnancies were included. T1DM was identified based on ICD code O24.0. Mothers were categorized according to pre-pregnancy body mass index (BMI: weight in kg/height in m²) as normal weight (BMI 18.5-24.9), overweight (BMI 25-29.9) or obese (BMI ≥30). Only women with singleton pregnancies and with data on BMI were included.

Primary/secondary outcomes The primary outcome was large for gestational age (LGA: birth weight >90th percentile) infants. Secondary outcomes were major malformations, preeclampsia (PE), preterm delivery, perinatal mortality, delivery by Caesarean section and neonatal overweight. Logistic regression analysis was performed with normal weight non-diabetic women as the reference category and also within the diabetic cohort with normal weight type 1 diabetic women as the reference. The odds ratios (OR) were adjusted for ethnicity, maternal age, height, parity, smoking and chronic hypertension.

Results 35% of women with T1DM were overweight and 18% were obese, as compared to 26% and 11%, respectively, in non-diabetic pregnancies. The incidences of adverse outcome increased with greater BMI category. As compared with non-diabetic normal weight women, the adjusted OR for obese T1DM for LGA was 13.26 (11.27-15.59), major malformations 4.11 (2.99-5.65) and PE 14.19 (11.50-17.50). T1DM was a significant effect modifier of the association between BMI and LGA, major malformations and PE (p<0.001).

4

Conclusion High pre-pregnancy BMI is an important risk factor for adverse outcome in type 1 diabetic pregnancies. The combined effect of both type 1 diabetes and overweight or obesity constitutes the greatest risk. It seems prudent to strive towards normal pre-pregnancy BMI in women with T1DM.

For peer review only

Introduction

Body mass index (BMI) has increased among fertile women in many countries, including Sweden (1). Maternal overweight and obesity are well known risk factors for adverse pregnancy outcome. High pre-pregnancy BMI has been associated with increased risk for stillbirth, fetal malformations, large for date neonates, neonatal and infant death, pregnancy induced hypertension and preeclampsia, maternal diabetes, delivery by Caesarean section as well as increased numbers of days spent in hospital for both mother and infant (2-11). The pathophysiological mechanism behind the increased risk of adverse pregnancy outcome in obese women is not fully understood. Increased insulin resistance and a state of inflammation associated with obesity (12) are likely important contributing factors.

Given the links between overweight, insulin resistance and adverse pregnancy outcome, any additional pregnancy risks in overweight women with diabetes are important to disclose, especially since overweight and obesity are more prevalent among diabetic women than in the general obstetric population (13). Increased risks of neonatal and maternal morbidity have been reported in overweight and obese women with gestational diabetes (14-16). In contrast, data is very limited regarding the impact of high maternal BMI on the risk of adverse pregnancy outcome in women with type 1 diabetes. An interaction between maternal diabetes, including both pre-gestational and gestational diabetes, and obesity has been suggested to increase the risk of malformations in the offspring (17). However, the majority of women in that study had gestational diabetes and no separate analysis was performed in women with type 1 diabetes.

The aim of the present study was to analyse the association between maternal overweight and obesity and the risk of fetal and obstetric complications in type 1 diabetic pregnancies, with

6

special reference to the high and increasing incidence of large for gestational age infants (13). This study includes a large national cohort of more than 3,000 type 1 diabetic pregnancies and the risk of adverse outcome in relation to maternal BMI was also compared with non-diabetic pregnancies. Our hypothesis was that maternal overweight/obesity and maternal type 1 diabetes have independent impact on the risk of adverse outcome and that the combination of the two constitutes the greatest risk.

Research design, material and methods

This population based cohort study was based on data from the Swedish Medical Birth Registry (MBR). The MBR prospectively collects information on maternal medical history, obstetric and neonatal diagnoses and covers more than 99% of all pregnancies in Sweden.

Until 2008, the MBR did only collect data on pregnancies from 28^{0/7} weeks of gestation and did not register data on earlier fetal losses or induced abortions. The quality of data in the

Comment [MP1]: R2, comment 1

registry is continuously evaluated by the National Board of Health and the conclusion of the

latest extensive validation in 2002 was that quality of data is high (18). Maternal and neonatal

Comment [MP2]: R2, comment 2

diagnoses were classified according to ICD-10, introduced in Sweden in 1997. ICD 9 codes

Comment [MP3]: R1 "Some comments", nb1

were also included to ensure that no patients would be missed. All diagnoses were made by a physician before hospital discharge and copies of the records were forwarded to the MBR.

Maternal characteristics included in the present study were mother's age, parity, pre-pregnancy weight, height, chronic hypertension, smoking habits, and whether the mother was born in one of the Nordic countries (Sweden, Finland, Denmark, Norway or Iceland) or elsewhere. Chronic hypertensive disease ICD-10: I10 or O10.0) was defined as blood pressure above 140/90 mmHg diagnosed before pregnancy or before 20 weeks of gestation. Maternal height and pre-pregnancy weight were recorded by recall and body mass index (BMI) was calculated as weight in kg divided by the square of the height in meters. Exposure in women

with and without T1DM was defined as overweight ($BMI \geq 25-29.9 \text{ kg/m}^2$) or obese ($BMI \geq 30 \text{ kg/m}^2$) and pregnancy outcomes were compared with that of normal weight women ($BMI 18.5-24.9 \text{ kg/m}^2$). Women with $BMI < 18.5 \text{ kg/m}^2$ (under-weight) and records with missing data on BMI were excluded as well as records with extreme values on maternal age (< 13 or > 54 years) maternal weight (< 40 or $> 200 \text{ kg}$) or maternal height (< 120 or $> 200 \text{ cm}$). We applied the same limits for data acceptance of birth weight and birth length as in the National Perinatal Quality Registry in Sweden: i.e., records with birth weight < 200 or > 9998 grams or birth length < 15 or $> 65 \text{ cm}$, were excluded.

Study cohort

Infants from singleton pregnancies and born to mothers with type 1 diabetes in Sweden between 1998 and 2007 were included, in total $n=3,457$. Type 1 diabetic pregnancies were identified based on ICD10 code O240 and ICD 9 code 250 for pre-gestational diabetes.

Non-diabetic cohort

The reference group ($n= 764,498$) included all singleton pregnancies to mothers without a diagnosis of diabetes [based on ICD 10 and 9 codes for type 1 diabetes (O240, 250x1/x3), type 2 diabetes (O241) and all codes starting with E11 and E 177-119,250x0/x2 or gestational diabetes codes (O244 A, B, X, 648.8)] and born in the same time period as the study cohort.

Percentiles for birth weight were based on all live born, singleton infants, without major malformations, to mothers without a diagnosis of diabetes. Birth weight percentiles were adjusted for sex and gestational age.

Primary outcome

Fetal macrosomia, i.e. giving birth to a large for gestational age (LGA) infant was the primary outcome of this study. LGA was defined as a birth weight >90th percentile for sex and gestational age.

Secondary outcomes

Secondary outcomes were major malformations, preeclampsia, preterm delivery, perinatal mortality, delivery by Caesarean section (emergency and elective) and neonatal overweight. Major malformations were pre-defined in the MBR as fatal or potentially life threatening malformations or if the malformation would likely lead to a serious handicap or major cosmetic defect if not surgically corrected. Preeclampsia was defined as a blood pressure above 140/90 mmHg after 20 weeks of gestation and proteinuria (at least 0.3 g/day or > 1+ on a urine dipstick, ICD-10 codes: O14.0, O14.1 and O15/ICD 9 codes: 642.4, 642.5 and 642.6). Preterm birth was defined as delivery before 37 gestational weeks. Perinatal mortality was defined as intrauterine death after 28^{0/7} weeks of gestation or death during the first week of postnatal life. Neonatal overweight was defined as birth weight and ponderal index (PI: birth weight in grams/length cm)³ above the 90th percentile for sex and gestational age.

This study was approved by the Regional Ethical Review Board in Uppsala, Sweden.

Comment [MP4]: R1 first comment

Statistical methods

Comparison between groups were made using Kruskal Wallis test for continuous data and χ^2 test and χ^2 test for trend for binary and categorical data as appropriate. Unconditional logistic regression was used to explore associations between maternal BMI categories and adverse outcomes with normal weight (BMI 18.5-24.9 kg/m²) women as the reference category as follows: the odds ratios of adverse outcomes in relation to BMI category were estimated in

women with type 1 diabetes with 1) normal weight women with type 1 diabetes as reference category and 2) with normal weight non-diabetic women as reference category. Crude and adjusted odds ratios (OR) were calculated. The following variables were included in the final regression model for LGA as possible confounders because of their established association with the primary outcome: Nordic origin (yes/no), maternal age, height, parity, smoking and chronic hypertension. The final regression models for the secondary outcomes included covariates significantly associated with the outcomes in univariate analysis. Missing indicator variables were used for maternal age and height. The likelihood ratio test was used to explore potential interaction between BMI categories and T1DM for the risk of the adverse outcomes. A p-value <0.05 was considered significant. All statistical analyses were performed using STATA 10.1 SE.

Results

Between 1998 and 2007, there were 947,096 deliveries in Sweden, including 4,208 (0.4%) deliveries to mothers with type 1 diabetes. Of all pregnancies, we excluded 441 records (0.05%) with extreme values on maternal age, maternal weight or height. No records were excluded due to extreme values on birth weight but 3,402 records were missing for this variable. We excluded 90 records (0.01%) due to extreme values on birth length and 14,544 were missing for birth length. In women with type 1 diabetes, 652 records (15%) were excluded due to missing data on maternal BMI or BMI<18.5 and 116 (2.8%) due to multiple pregnancies. 17 records were identified as both missing for BMI and with multiple pregnancies, thus giving a final study cohort of 3,457 infants (1,758 male infants, 51%) born to mothers with type 1 diabetes. The reference population included 764,498 singleton pregnancies to mothers without a diagnosis of diabetes, excluding 28,018 records from multiple pregnancies and 147,835 records with missing data on maternal BMI or BMI<18.5.

Comment [MP5]: R2, comment 3

Reference percentiles for birth weight, birth length and ponderal index were formed using records from all non-diabetic pregnancies and excluding stillborn infants (0.31%), infants with major malformations (1.84%) and multiple pregnancies (3.01%).

Maternal and infant characteristics

Mothers with type 1 diabetes had a significantly higher median pre-pregnancy BMI (25.1 kg/m²) compared to the non-diabetic group (23.6 kg/m², p<0.001). In the type 1 diabetic cohort, 35% (n= 1,195) of women were overweight and 18% (n=618) were obese as compared with 26% (n=200,600) and 11% (n=82,331), respectively, in the non-diabetic population. Women with type 1 diabetes were also more often of Nordic origin, had a higher prevalence of chronic hypertension and smoking during the first trimester compared to women without diabetes (p-value for all comparisons <0.01). Infants to mothers with diabetes type 1 were born at a significantly lower median gestational age and preterm birth was four times as common compared to non-diabetic offspring (p-value for all comparisons <0.001).

The median birth weight was significantly higher in infants delivered by mothers with type 1 diabetes than in the reference group, Table 1.

Table 1) Maternal and infant characteristics, type 1 diabetes and non-diabetic reference population

	Type 1 diabetes N=3,457	Non-diabetic population N=764,498	P-value
Maternal characteristics			<i>Comment [MP6]: R1 "Some comments" no 6.</i>
Nordic, n (%)	3,194 (92)	643,608 (84)	<0.001
Swedish origin, n (%)	3,151 (91)	628,534 (82)	<i>Comment [MP7]: R1 "Some comments" no 2.</i>
Maternal age, years (median, IQR)	30 (27-34)	30(27-33)	<0.001
Smoking first trimester, n (%)	384 (11)	72,766 (10)	0.001
Primipara, n (%)	1,559 (45)	337,199 (44)	0.242
BMI, kg/m ² (median, IQR)	25.1 (23.0-28.4)	23.6 (21.6-26.4)	<0.001
Over weight (BMI ≥ 25-29.9), n_(%)	1,195 (35%)	200,600 (26%)	<0.001
Obese (BMI ≥30), n_(%)	618 (18%)	82,331 (11%)	<0.001
Height, cm (median,IQR)	167 (162-170)	167 (162-170)	0.250
Chronic hypertension, n (%)	92 (2.7)	2,472 (0.32)	<0.001
Infant characteristics			
Male, n (%)	1,758 (51%)	393,324 (51%)	0.485
Gestational age, weeks (md,IQR)	38 (37-39)	40 (39-41)	<0.001
Preterm delivery n (%)	741 (21%)	35,878 (4.7%)	<0.001
Birth weight, g (md,IQR)	3805 (3350-4265)	3575 (3240-3915)	<0.001
Birth length, cm (md,IQR)	51 (49-52)	51 (49-52)	0.576
LGA, BW >90 percentile, n (%)	1,694 (49)	81,142 (11)	<0.001
AGA, BW 10-90 percentile, n (%)	1,661 (48%)	614,784 (80%)	<0.001
SGA, BW <10 percentile, n (%)	109 (3.2%)	76,214 (10)	<0.001

1
2
3
4
5
6
7
8 *Adverse outcomes in relation to body mass index category (Table 2)*

9
10 Overall, the incidence of all adverse outcomes was significantly higher in women with type 1
11 diabetes, irrespective of BMI category. The incidence of the primary outcome LGA was
12 highest in obese T1DM women; however the differences between BMI categories did not
13 reach statistical significance within the diabetes cohort. The incidence of all secondary
14 outcomes was highest in obese women with type 1 diabetes, except for PMR in type 1
15 diabetic pregnancies with the highest recorded frequency in overweight women. Within the
16 non-diabetic pregnancies, the incidence of all outcomes increased significantly with greater
17 BMI category (chi square test for trends for all outcomes $p < 0.001$), Table 2.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2) Perinatal outcomes for pregnant women with or without type 1 diabetes and stratified on pre-pregnancy

BMI. Data are presented as numbers (percentages).

Comment [MP8]: R1 "Minor comment" no1

	BMI 18.5-24.9	BMI 25-29.9	BMI≥30	P-value
LGA-infant				
Type 1 diabetes	778 (47)	603 (50)	313 (51)	0.170
Non-diabetic	39,265 (8.2)	26,828 (13)	15,049 (18)	<0.001
Major malformations				
Type 1 diabetes	65 (4.0)	44 (3.7)	41 (6.6)	0.008
Non-diabetic	8,186 (1.7)	3,736 (1.9)	1,610 (2.0)	<0.001
Preeclampsia				
Type 1 diabetes	222 (14)	185 (15)	114 (18)	0.012
Non-diabetic	9,872 (2.1)	6,529 (3.3)	4,810 (5.8)	<0.001
Preterm delivery				
Type 1 diabetes	322 (20)	275 (23)	144 (23)	0.041
Non-diabetic	21,714 (4.5)	9,464 (4.7)	4,700 (5.7)	<0.001
Perinatal mortality				
Type 1 diabetes	14 (0.85)	15 (1.3)	6 (0.97)	0.566
Non-diabetic	1,554 (0.32)	948 (0.47)	593 (0.72)	<0.001
Caesarean section				
Type 1 diabetes	748 (46)	639 (53)	362 (59)	<0.001
Non-diabetic	64,131 (13)	34,081 (17)	18,166 (22)	<0.001
Neonatal overweight				
Type 1 diabetes	351 (21)	288 (24)	166 (27)	0.016
Non-diabetic	15,359 (3)	10,430 (5)	6,466 (8)	<0.001

*Chi square test, Kruskal Wallis test, Chi square test for trends

1
2
3
4
5
6
7
8
9
10 There was a similar pattern of increasing odds ratio for adverse outcome with greater BMI
11 category in women with and without type 1 diabetes. Inclusion of maternal covariates in the
12 regression models did not significantly change these estimates. Relative to a normal weight
13 non-diabetic woman, the adjusted OR for the risk of having a LGA infant in overweight or
14 obese women with type 1 diabetes was approximately 13, as compared with approximately 2
15 in overweight and obese non-diabetic women, Table 3. In relation to a normal weight woman
16 without diabetes, obesity in women with type 1 diabetes was associated with an adjusted OR
17 for major malformation of 4.11 (2.99-5.65) as compared with 1.15 (1.09-1.22) in non-diabetic
18 women with obesity. Compared with a normal weight non-diabetic woman, the adjusted odds
19 ratios for PE in a woman with type 1 diabetes of normal weight was 7.17 (6.04-8.50) and in
20 combination with overweight 9.91 (8.61-11.40) and in obese T1DM women the adjusted OR
21 was 14.19 (11.50-17.50). The corresponding estimates for a non-diabetic woman with
22 overweight or obesity were 1.74(1.69-1.80) and 3.37 (3.25-3.49), respectively. The OR for
23 Caesarean section increased with BMI category, both in women with and without type 1
24 diabetes, Table 3.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3) Crude and adjusted* odds ratios (OR; 95%CI) for adverse perinatal outcomes in pregnant women with and without type 1 diabetes (T1DM) and stratified on pre-pregnancy BMI. Reference group: non-diabetic women with normal pre-pregnancy BMI.

Comment [MP9]: R2, last comment

	BMI 18.5-24.9	BMI 25-29.9	BMI≥30	Interaction# P-value
LGA-infant				
T1DM; Crude	10.16 (9.10-11.36)	12.40 (11.22-13.70)	12.29 (10.50-14.40)	<0.001
Adjusted	10.72 (9.56-12.01)	13.55 (12.23-15.02)	13.26 (11.27-15.59)	<0.001
Non-diabetic ; Crude	1.0	1.74 (1.71-1.77)	2.52 (2.47-2.57)	<0.001
Adjusted	1.0	1.76 (1.73-1.79)	2.60 (2.55-2.66)	<0.001
Major malformations				
T1DM; Crude	2.28 (1.71-3.04)	2.34 (1.81-3.02)	4.11 (2.99-5.65)	0.03
Adjusted	2.28 (1.71-3.04)	2.34 (1.81-3.03)	4.11 (2.99-5.65)	0.03
Non-diabetic; Crude	1.0	1.10 (1.06-1.14)	1.15 (1.09-1.22)	0.03
Adjusted	1.0	1.10 (1.06-1.14)	1.15 (1.09-1.22)	0.03
Preeclampsia				
T1DM; Crude	7.12 (6.02-8.42)	9.30 (8.11-10.67)	11.23 (9.15-13.77)	<0.001
Adjusted	7.17 (6.04-8.50)	9.91(8.61-11.40)	14.19 (11.50-17.50)	<0.001
Non-diabetic; Crude	1.0	1.61(1.56-1.66)	2.96 (2.86-3.07)	<0.001
Adjusted	1.0	1.74 (1.69-1.80)	3.37 (3.25-3.49)	<0.001
Preterm delivery				
T1DM; Crude	4.86 (4.22-5.60)	6.23 (5.53-7.02)	6.39 (5.30-7.71)	0.16
Adjusted	4.72 (4.09-5.44)	5.98 (5.31-6.74)	5.97 (4.94-7.21)	0.15
Non-diabetic; Crude	1.0	1.05 (1.02-1.07)	1.28 (1.24-1.32)	0.16
Adjusted	1.0	1.04 (1.02-1.07)	1.26 (1.22-1.30)	0.15

Perinatal mortality					
T1DM;	Crude	2.55 (1.36-4.76)	3.93 (2.49-6.19)	3.14 (1.40-7.04)	0.29
	Adjusted	2.46 (1.32-4.60)	3.72 (2.36-5.89)	2.86 (1.27-6.44)	0.31
Non-diabetic ;	Crude	1.0	1.47 (1.35-1.59)	2.24 (2.04-2.46)	0.29
	Adjusted	1.0	1.46 (1.35-1.59)	2.22 (2.03-2.44)	0.31
Caesarean section					
T1DM;	Crude	5.59 (5.00-6.25)	7.09 (6.42-7.83)	9.44 (8.04-11.08)	0.42
	Adjusted	5.69 (5.09-6.37)	7.12 (6.44-7.88)	9.35 (7.95-11.00)	0.36
Non-diabetic;	Crude	1.0	1.33 (1.31-1.35)	1.84 (1.81-1.88)	0.42
	Adjusted	1.0	1.34 (1.32-1.36)	1.87 (1.83-1.90)	0.36
Neonatal overweight					
T1DM;	Crude	8.46 (7.39-9.70)	9.93 (8.83-11.17)	11.71 (9.79-14.00)	<0.001
	Adjusted	8.40 (7.32-9.64)	9.86 (8.76-11.11)	11.29 (9.42-13.53)	<0.001
Non-diabetic;	Crude	1.0	1.66 (1.62-1.71)	2.59 (2.51-2.67)	<0.001
	Adjusted	1.0	1.65 (1.61-1.69)	2.55 (2.48-2.63)	<0.001

*Adjusted for ethnicity, maternal age, height, parity, smoking first trimester, chronic hypertension

#Interaction between BMI category and T1DM

Table 4 shows the OR for adverse outcome in women with type 1 diabetes by BMI category with normal weight women with type 1 diabetes as the reference category. In obese T1DM women the adjusted OR of major malformations [1.77 (1.18-2.65)] and preeclampsia [1.74(1.35-2.25)] were significantly increased compared with normal weight T1DM women. The OR of Caesarean section was significantly increased in both overweight and obese T1DM women, Table 4. The OR for LGA did not differ significantly between the different

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

17

BMI categories. However, the adjusted OR for delivering a disproportionate LGA-infant with neonatal overweight (ponderal index >90th percentile) was significantly increased in obese T1DM women 1.36 (1.09-1.69).

Comment [MP10]: R1 "Some comments" nb 5

For peer review only

Table 4) Crude and Adjusted* Odds ratios (OR; 96%CI) for adverse perinatal outcome in pregnant women with type 1 diabetes (T1DM) and stratified on BMI. Reference group: T1DM women with normal pre-pregnancy BMI.

Comment [MP11]: R2, last comment

	T1DM BMI 18.5-24.9	T1DM BMI 25-29.9	T1DM BMI≥30
LGA-infant			
Crude	1.0	1.13 (0.98-1.32)	1.14 (0.95-1.37)
Adjusted	1.0	1.18 (1.01-1.38)	1.21 (1.00-1.47)
Major malformations			
Crude	1.0	0.93 (0.63-1.37)	1.73 (1.15-2.58)
Adjusted	1.0	0.92 (0.62-1.36)	1.77 (1.18-2.65)
Preeclampsia			
Crude	1.0	1.17 (0.95-1.45)	1.45 (1.13-1.86)
Adjusted	1.0	1.21 (0.98-1.50)	1.74 (1.35-2.25)
Preterm delivery			
Crude	1.0	1.23 (1.02-1.47)	1.25 (1.00-1.56)
Adjusted	1.0	1.22 (1.02-1.47)	1.25 (1.00-1.56)
Perinatal mortality			
Crude	1.0	1.48 (0.71-3.08)	1.14 (0.44-2.98)
Adjusted	1.0	1.47 (0.70-3.03)	1.08 (0.41-2.83)
Caesarean section			
Crude	1.0	1.38 (1.19-1.60)	1.69 (1.40-2.04)
Adjusted	1.0	1.37 (1.18-1.60)	1.67 (1.38-2.03)
Neonatal overweight			
Crude	1.0	1.17 (0.98-1.40)	1.35 (1.09-1.67)
Adjusted	1.0	1.19 (0.99-1.42)	1.36 (1.09-1.69)

*Adjusted for ethnicity, maternal age, height, parity, smoking first trimester, chronic hypertension

Discussion

This study shows that high maternal pre-pregnancy BMI is a very important risk factor for adverse pregnancy outcome in women with and without type 1 diabetes. High maternal BMI and type 1 diabetes are independent risk factors for maternal and perinatal complications.

However, type 1 diabetes remains a stronger risk factor for adverse outcome than obesity. The risk of adverse outcome in women with concomitant type 1 diabetes and obesity exceeds that of either condition alone, indicating synergism between the two exposures. Obesity in type 1 diabetes is associated with significantly increased risk of PE, major malformations and Caesarean section as compared with type 1 diabetic women with normal BMI.

The prevalence of overweight and obesity in pregnant women is increasing in Sweden and worldwide (1, 12) and the harmful effects of high maternal BMI on pregnancy outcome are well established in the general obstetric population (2-11). On the other hand, data on the potential association between high maternal BMI and adverse pregnancy outcome in women with type 1 diabetes is scarce (17, 19-20). In a cohort of 46 women with type 1 diabetes and nephropathy, maternal overweight was identified as an important risk factor for poor pregnancy outcome (19). In mixed populations of women with pre-gestational diabetes, maternal obesity has been associated with pregnancy complications (20) and increased risk of birth defects (17). These two studies however, do not separate women with diabetes type 1 from those with diabetes type 2 and do not include any comparable data from a non-diabetic reference population.

The present study is to our knowledge, the first to present risk estimates of obstetric and perinatal complications in a large cohort of women with exclusively type 1 diabetes, stratified by BMI category and compared with a non-diabetic reference population. The large sample

size enabled risk estimation of rare outcomes such as perinatal mortality and major malformations in relation to subgroups of maternal BMI. The population based study design provides unanimous risk estimates for overweight and obese women with and without type 1 diabetes. The vast majority of our study population is of Nordic origin and 91% were Swedish. The study population is also homogenous with respect to medical care in pregnancy. In Sweden, healthcare is free of charge as well as insulin, test strips for home monitoring of glucose and equipment for insulin administration. The care of pregnant women with type 1 diabetes is uniform over the whole country and pregnancy outcome does not differ with geographical area (13).

Some limitations with the present study should be noted. Body mass index was calculated from recalled data on pre-pregnancy weight and height. Women tend to underestimate their weight and it has been demonstrated that this bias increases directly with the degree of overweight (21). A potential misclassification of women to lower BMI categories would lead to an underestimation of our findings of increased risks associated with high maternal BMI. The Swedish MBR does not collect data on maternal glycaemic control, duration of diabetes, insulin regimens nor data on diet and physical activity. Data on socioeconomic factors is also very limited. Consequently, the impact of socioeconomic factors, diet, physical activity and level of control on the risk of adverse outcome could not be assessed. It is plausible that the achieved level of metabolic control differed between normal weight, overweight and obese type 1 diabetic women. In a study on pregnancies complicated by gestational diabetes, the fasting glucose levels were significantly higher in obese compared with overweight and normal weight women (14). However, results from the HAPO study confirm that maternal BMI and glycaemia exert independent effects on the risk of adverse pregnancy outcome (2).

Comment [MP12]: R1 "Some comments" nb 4

1
2
3
4
5
6
7
8 In the present study, obese women with type 1 diabetes had significantly increased risks of
9 major malformations and preeclampsia as compared with normal weight women with type 1
10 diabetes. This is in line with the finding of an interaction between maternal diabetes and
11 obesity on the risk of adverse outcome in a mixed population of women with different types
12 of diabetes (17). However, the increased risk of major malformations in relation to BMI in the
13 present analysis should be interpreted with caution as maternal overweight and obesity rend
14 ultrasound assessment of fetal anatomy difficult (22) and we do not have data on the number
15 of induced abortions due to malformations. Maternal hyperglycaemia in early pregnancy is a
16 well known risk factor for major malformations and preeclampsia (23). Obesity is associated
17 with increased insulin resistance (12) and one could speculate that women with obesity had a
18 poorer level of control in early pregnancy than women with normal or slightly elevated BMI.

19
20
21
22
23
24
25
26
27
28
29 In line with previous studies, we found increased risks of PE and major malformations in
30 obese non diabetic women (5, 6, 10). In the present study, the risks of these complications
31 were also significantly elevated in non- diabetic women with overweight. Obesity is
32 associated with decreased insulin sensitivity and already slightly elevated levels of fasting
33 glucose, within the upper normal range, are associated with increased risk of preeclampsia in
34 women without diabetes (24). In Sweden, there is no uniform screening for gestational
35 diabetes. It is possible that the increased risk of PE and major malformations in overweight
36 and obese women in the reference group is partly due to undetected cases of impaired glucose
37 tolerance or diabetes. Interestingly, maternal pre-pregnancy BMI has been demonstrated as a
38 stronger predictor of major malformations than severity of gestational diabetes (25).
39
40
41
42
43
44
45
46
47
48

49
50
51
52
53
54
55
56
57
58
59
60
In women with type 1 diabetes, the incidence of LGA was very high in all weight classes and
increased with greater BMI category. However, the odds ratio for an LGA outcome did not
differ significantly between BMI categories, as opposed to in non-diabetic women. This is in

accordance with findings in two recent studies (26, 27). On the contrary, the risk of delivering a disproportionate, overweight LGA infant (PI > 90th percentile) was significantly increased in obese women within the type 1 diabetic cohort. In accordance with the study by Ehrenberg our findings indicate that maternal overweight is an important risk factor for LGA, but maternal diabetes has an even greater impact (28). A possible contributing factor to this finding could also be the increasing prevalence of preeclampsia with greater BMI category.

Comment [MP13]: R1_RE: ref by Murphy

This study confirms the observations in non-diabetic pregnancies (2-5) that increasing maternal BMI is associated with increased risk of delivery by Caesarean section also in women with type 1 diabetes. The increased incidence of complications such as preeclampsia and LGA in these groups most likely contributes to this finding.

The majority of perinatal deaths were stillbirths in all BMI categories and in both women with and without type 1 diabetes. The risk of perinatal mortality was independent of BMI category within the type 1 diabetic cohort but increased significantly with higher BMI in the reference group. This finding is in line with previous studies, reporting increased risk of both stillbirth and neonatal mortality in obese, non-diabetic women even after adjusting for maternal and perinatal risk factors (7, 8, 9). The lack of a significantly increased risk of perinatal mortality with increasing BMI category within the diabetes cohort, indicate that diabetes is a stronger risk factor for perinatal mortality than maternal overweight/obesity.

In the present study, we found an increasing risk of preterm delivery with greater BMI category, both in women with and without type 1 diabetes. Results from some earlier studies have shown an increased risk of preterm delivery in obese non-diabetic women (3, 4) while others have reported the opposite association (2, 5).

1
2
3
4
5
6
7
8
9
10 It is hypothesized that the increased risk of pregnancy complications in overweight and obese
11 women is related to increased maternal fat mass. In the present study, pre-pregnancy BMI
12 was used as a proxy for maternal fat mass as there is a strong correlation ($r^2= 0.86$) between
13 pre-pregnancy BMI and maternal fat mass in women without diabetes (29). However, BMI
14 does not provide information on the localization of fat mass. One suggested link between high
15 maternal pre-pregnancy BMI and increased risk of adverse outcome pregnancy is a large
16 visceral fat mass. The visceral fat mass is associated with increased insulin resistance,
17 inflammation and lipotoxicity with potential harmful effects on maternal vascular and
18 placental function and fetal development (30). Other pathophysiological mechanisms behind
19 the increased risk of adverse pregnancy outcome in overweight/obese mothers are not clear
20 but are most likely complex. Genetic- and socioeconomic factors, maternal diet and physical
21 activity are probable contributing factors.
22
23
24
25
26
27
28
29
30
31
32
33
34

35 In conclusion, this population based study on more than 3000 type 1 diabetic pregnancies
36 demonstrates a strong association between maternal pre-pregnancy BMI and elevated risk of
37 adverse pregnancy outcome. Type 1 diabetes in combination with overweight or obesity
38 constitutes a higher risk than either condition alone. Striving towards normal pre-pregnancy
39 BMI in women with type 1 diabetes could hopefully reduce the risk of adverse outcome.
40
41
42
43
44
45

46 **Acknowledgement**

47
48 This study was supported by the Swedish Order of Freemasons and the Stockholm County
49 Council. DP was funded by the National Institute of Health Research (NIHR), UK and the
50 Tommy's Charity. The funding consisted of salary for the researchers MP and DP. We
51 appreciate the help from the Swedish Medical Birth Registry to provide us with data.
52
53
54
55
56
57
58
59
60

Disclosure of interest

The authors have no potential conflicts of interest.

Author contributions

MP. DP.UH.MW.MN; contributions of design and interpretation of data

MP. UH; Data acquisition

MP. DP; Data analyses

MP. DP.UH.MW. MN; Interpretation of results

MP. MN; Drafted the manuscript

MN; Handled funding and supervision

MP. DP. UH. MW.MN; Critical revision of the manuscript and final approval of the version to be published

Ethics Approval

This study was approved by the Regional Ethical Review Board in Uppsala, Sweden. Date of approval: 22/7 2009, reference number: 2009/187

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Data sharing statement

No additional data available.

References:

- 1) Surkan P, Chung-Cheng Hsieh, Johansson A.L.V et al.Reasons for Increasing Trends in Large for Gestational Age Births *Obstetrics and Gynecology* 2004;104:4
- 2) HAPO Study Cooperative Research Group. Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) Study: associations with maternal body mass index. *BJOG*;2010;117:575-584
- 3) Callaway L.K, Prins J.B, Chang A.M et al.The prevalence and impact of overweight and obesity in an Australian obstetric population. *MJA*;2006;2:56-59
- 4) Heslehurst N, Simpson H, Ells L.J et al.The impact of maternal BMI status on pregnancy outcomes with immediate short-term obstetric resource implications:a meta-analysis. *Obesity Reviews*;2008;9:635-683
- 5) Athukorala C, Rumbold A.R, Willson K.J et al.The risk of adverse pregnancy outcomes in women who are overweight or obese. *BMC Pregnancy and Childbirth*;2010;10:56
- 6) Stothard K.J, Tennant P.W.G, Bell R et al. Maternal Overweight and Obesity and the Risk of Congenital Anomalies. A systematic Review and Meta-analysis. *JAMA*;2009;301:636-650
- 7) Kristensen J, Vestergaard M, Wisborg K et al.Pre-pregnancy weight and the risk of stillbirth and neonatal death. *BJOG*;2005;112:403-408
- 8) Nohr E.A, Vaeth M, Bech B.H et al.Maternal Obesity and Neonatal Mortality According to Subtypes of Preterm Birth. *Obstet Gynecol*;2007;110:1083-1090
- 9) Cnattingius S, Bergström R, Lipworth L et al. Prepregnancy weight and the risk of adverse pregnancy outcomes. *N Engl J Med* ;1998;338:147-152.
- 10) O'Brien TE, Ray JG, Chan WS. Maternal body mass index and the risk of preeclampsia: a systematic overview. *Epidemiology*;2003;14:368-374

- 11) Chen A, Feresu S.A, Fernandez C et al. Maternal Obesity and the Risk of Infant Death in the United States. *Epidemiology*;2009;20:74-81
- 12) Catalano P. Obesity, insulin resistance, and pregnancy outcome. *Reproduction*;2010;140:365-371
- 13) Persson M, Norman M, Hanson U. Obstetric and perinatal outcomes in type 1 diabetic pregnancies - a large, population-based study. *Diabetes Care* 2009;32:2005-9
- 14) Roman AS, Rebarber A, Fox N.S et al. The effect of maternal obesity on pregnancy outcomes in women with gestational diabetes. *J Matern Fetal Neonatal Med*;2011;24(5):723-727
- 15) Yogev Y, Langer O. Pregnancy outcome in obese and morbidly obese gestational diabetic women. *European Journal of Obstetrics and Gynecology and Reproductive Biology*;2008;137:21-26
- 16) Langer O, Yogev Y, Xenakis E.M.J et al. Overweight and obese in gestational diabetes: The impact on pregnancy outcome. *Am J Obstet Gynecol*;2005;192:1768-1776
- 17) Moore L.L, Singer M.R, Bradlee M.L et al. A prospective study of the risk of congenital defects associated with maternal obesity and diabetes mellitus. *Epidemiology*;2000;11:689-694
- 18) The National Board of Health and Welfare (Socialstyrelsen) [Internet]. Available from <http://www.sos.se/epc/fodelse/mfr.htm>. Accessed December 18, 2012.
- 19) Yogev Y, Chen R, Ben-Haroush A et al. Maternal overweight and pregnancy outcome in women with type 1 diabetes mellitus and different degrees of nephropathy. *The J of Maternal-Fetal and Neonatal Medicine*;2010;23:999-1003
- 20) Ray J.G, Vermeulen M.J, Shapiro J.L et al. Maternal and neonatal outcomes in pregestational and gestational diabetes mellitus, and the influence of maternal obesity and weight gain: the DEPOSIT study. *Q J Med*;2001;94:347-356

- 1
2
3
4
5
6
7
8 21) Rowland ML. Self-reported weight and height. *Am J Clin Nutr*;1990:52(6):1125-1133
9
10 22) Dashe JS, McIntire DD, Twickler DM. Maternal obesity limits the ultrasound evaluation
11 of fetal anatomy. *J Ultrasound Med*;2009:28(8):1025-1030
12
13 23) Taylor R, Davidson J.M. Type 1 diabetes and pregnancy. *BMJ*;2007:334:742-5
14
15 24) The HAPO study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy
16 Outcomes. *N Eng J of Medicine*;2008:358:1991
17
18 25) Garcia-Patterson A, Erdozain L, Ginovart G et al. In human gestational diabetes mellitus
19 congenital malformations are related to pre-pregnancy body mass index and to severity of
20 diabetes. *Diabetologia*; 2004:47:509-514
21
22 26) Murphy H.R, Steel S.A, Roland J.M et al. Obstetric and perinatal outcomes in pregnancies
23 complicated by Type 1 and Type 2 diabetes:influences of glycaemic control,obesity and
24 social disadvantage. *Diabetic Medicin*;2011:28:1060-1067
25
26 27) Feghali M, Khoury J.C, Timofeev J et al. Asymmetric Large For Gestational Age in
27 Newborns in Pregnancies Complicated by Diabetes Mellitus:Is Maternal Obesity a
28 Culprit? *J Matern Fetal Neonatal Med*;2011 30 sep [Epub ahead of print]
29
30 28) Ehrenberg H.M, Brian M.M, Catalano P. The influence of obesity and diabetes on the
31 prevalence of macrosomia. *Am J Obstet Gynecol*;2004:191:964-968
32
33 29) Sewell MF, Huston-Presley L, Amini SB et al.Body mass index: a true indicator of body
34 fat in obese gravidas. *J Reprod Med*;2007:52(10):907-11
35
36 30) Jarvie E, Hauguel-de-Mouzon S, Nelson S, Sattar N, Catalano P, Freeman D J.
37 Lipotoxicity in obese pregnancy and its potential role in adverse pregnancy outcome and
38 obesity in the offspring. *Clinical Science*;2010:119:123-12
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1) Maternal and infant characteristics, type 1 diabetes and non-diabetic reference population

	Type 1 diabetes N=3,457	Non-diabetic population N=764,498	P-value
Maternal characteristics			<i>Comment [MP14]: R1 "Some comments" no 6.</i>
Nordic, n (%)	3,194 (92)	643,608 (84)	<0.001
Swedish origin, n (%)	3,151 (91)	628,534 (82)	<i>Comment [MP15]: R1 "Some comments" no 2.</i>
Maternal age, years (median, IQR)	30 (27-34)	30(27-33)	<0.001
Smoking first trimester, n (%)	384 (11)	72,766 (10)	0.001
Primipara, n (%)	1,559 (45)	337,199 (44)	0.242
BMI, kg/m ² (median, IQR)	25.1 (23.0-28.4)	23.6 (21.6-26.4)	<0.001
Over weight (BMI ≥ 25-29.9), n_(%)	1,195 (35%)	200,600 (26%)	<0.001
Obese (BMI ≥30), n_(%)	618 (18%)	82,331 (11%)	<0.001
Height, cm (median,IQR)	167 (162-170)	167 (162-170)	0.250
Chronic hypertension, n (%)	92 (2.7)	2,472 (0.32)	<0.001
Infant characteristics			
Male, n (%)	1,758 (51%)	393,324 (51%)	0.485
Gestational age, weeks (md,IQR)	38 (37-39)	40 (39-41)	<0.001
Preterm delivery n (%)	741 (21%)	35,878 (4.7%)	<0.001
Birth weight, g (md,IQR)	3805 (3350-4265)	3575 (3240-3915)	<0.001
Birth length, cm (md,IQR)	51 (49-52)	51 (49-52)	0.576
LGA, BW >90 percentile, n (%)	1,694 (49)	81,142 (11)	<0.001
AGA, BW 10-90 percentile, n (%)	1,661 (48%)	614,784 (80%)	<0.001
SGA, BW <10 percentile, n (%)	109 (3.2%)	76,214 (10)	<0.001

Table 2) Perinatal outcomes for pregnant women with or without type 1 diabetes and stratified on pre-pregnancy

BMI. Data are presented as numbers (percentages).

Comment [MP16]: R1 "Minor comment" no1

	BMI 18.5-24.9	BMI 25-29.9	BMI ≥30	P-value
LGA-infant				
Type 1 diabetes	778 (47)	603 (50)	313 (51)	0.170
Non-diabetic	39,265 (8.2)	26,828 (13)	15,049 (18)	<0.001
Major malformations				
Type 1 diabetes	65 (4.0)	44 (3.7)	41 (6.6)	0.008
Non-diabetic	8,186 (1.7)	3,736 (1.9)	1,610 (2.0)	<0.001
Preeclampsia				
Type 1 diabetes	222 (14)	185 (15)	114 (18)	0.012
Non-diabetic	9,872 (2.1)	6,529 (3.3)	4,810 (5.8)	<0.001
Preterm delivery				
Type 1 diabetes	322 (20)	275 (23)	144 (23)	0.041
Non-diabetic	21,714 (4.5)	9,464 (4.7)	4,700 (5.7)	<0.001
Perinatal mortality				
Type 1 diabetes	14 (0.85)	15 (1.3)	6 (0.97)	0.566
Non-diabetic	1,554 (0.32)	948 (0.47)	593 (0.72)	<0.001
Cesarean section				
Type 1 diabetes	748 (46)	639 (53)	362 (59)	<0.001
Non-diabetic	64,131 (13)	34,081 (17)	18,166 (22)	<0.001
Neonatal overweight				
Type 1 diabetes	351 (21)	288 (24)	166 (27)	0.016
Non-diabetic	15,359 (3)	10,430 (5)	6,466 (8)	<0.001

*Chi square test, Kruskal Wallis test, Chi square test for trends

Table 3) Crude and adjusted* odds ratios (OR; 95%CI) for adverse perinatal outcomes in pregnant women with and without type 1 diabetes (T1DM) and stratified on pre-pregnancy BMI. Reference group: non-diabetic women with normal pre-pregnancy BMI.

Comment [MP17]: R2, last comment

		BMI 18.5-24.9	BMI 25-29.9	BMI≥30	Interaction# P-value
LGA-infant T1DM;	Crude	10.16 (9.10-11.36)	12.40 (11.22-13.70)	12.29 (10.50-14.40)	<0.001
	Adjusted	10.72 (9.56-12.01)	13.55 (12.23-15.02)	13.26 (11.27-15.59)	<0.001
Non-diabetic ;	Crude	1.0	1.74 (1.71-1.77)	2.52 (2.47-2.57)	<0.001
	Adjusted	1.0	1.76 (1.73-1.79)	2.60 (2.55-2.66)	<0.001
Major malformations T1DM;	Crude	2.28 (1.71-3.04)	2.34 (1.81-3.02)	4.11 (2.99-5.65)	0.03
	Adjusted	2.28 (1.71-3.04)	2.34 (1.81-3.03)	4.11 (2.99-5.65)	0.03
Non-diabetic;	Crude	1.0	1.10 (1.06-1.14)	1.15 (1.09-1.22)	0.03
	Adjusted	1.0	1.10 (1.06-1.14)	1.15 (1.09-1.22)	0.03
Preeclampsia T1DM;	Crude	7.12 (6.02-8.42)	9.30 (8.11-10.67)	11.23 (9.15-13.77)	<0.001
	Adjusted	7.17 (6.04-8.50)	9.91(8.61-11.40)	14.19 (11.50-17.50)	<0.001
Non-diabetic;	Crude	1.0	1.61(1.56-1.66)	2.96 (2.86-3.07)	<0.001
	Adjusted	1.0	1.74 (1.69-1.80)	3.37 (3.25-3.49)	<0.001
Preterm delivery T1DM;	Crude	4.86 (4.22-5.60)	6.23 (5.53-7.02)	6.39 (5.30-7.71)	0.16
	Adjusted	4.72 (4.09-5.44)	5.98 (5.31-6.74)	5.97 (4.94-7.21)	0.15
Non-diabetic;	Crude	1.0	1.05 (1.02-1.07)	1.28 (1.24-1.32)	0.16
	Adjusted	1.0	1.04 (1.02-1.07)	1.26 (1.22-1.30)	0.15

Perinatal mortality					
T1DM;	Crude	2.55 (1.36-4.76)	3.93 (2.49-6.19)	3.14 (1.40-7.04)	0.29
	Adjusted	2.46 (1.32-4.60)	3.72 (2.36-5.89)	2.86 (1.27-6.44)	0.31
Non-diabetic ;	Crude	1.0	1.47 (1.35-1.59)	2.24 (2.04-2.46)	0.29
	Adjusted	1.0	1.46 (1.35-1.59)	2.22 (2.03-2.44)	0.31
Cesarean section					
T1DM;	Crude	5.59 (5.00-6.25)	7.09 (6.42-7.83)	9.44 (8.04-11.08)	0.42
	Adjusted	5.69 (5.09-6.37)	7.12 (6.44-7.88)	9.35 (7.95-11.00)	0.36
Non-diabetic;	Crude	1.0	1.33 (1.31-1.35)	1.84 (1.81-1.88)	0.42
	Adjusted	1.0	1.34 (1.32-1.36)	1.87 (1.83-1.90)	0.36
Neonatal overweight					
T1DM;	Crude	8.46 (7.39-9.70)	9.93 (8.83-11.17)	11.71 (9.79-14.00)	<0.001
	Adjusted	8.40 (7.32-9.64)	9.86 (8.76-11.11)	11.29 (9.42-13.53)	<0.001
Non-diabetic;	Crude	1.0	1.66 (1.62-1.71)	2.59 (2.51-2.67)	<0.001
	Adjusted	1.0	1.65 (1.61-1.69)	2.55 (2.48-2.63)	<0.001

*Adjusted for ethnicity, maternal age, height, parity, smoking first trimester, chronic hypertension

#Interaction between BMI category and T1DM

Table 4) Crude and Adjusted* Odds ratios (OR; 96%CI) for adverse perinatal outcome in pregnant women with type 1 diabetes (T1DM) and stratified on BMI. Reference group: T1DM women with normal pre-pregnancy BMI.

Comment [MP18]: R2, last comment

	T1DM BMI 18.5-24.9	T1DM BMI 25-29.9	T1DM BMI≥30
LGA-infant			
Crude	1.0	1.13 (0.98-1.32)	1.14 (0.95-1.37)
Adjusted	1.0	1.18 (1.01-1.38)	1.21 (1.00-1.47)
Major malformations			
Crude	1.0	0.93 (0.63-1.37)	1.73 (1.15-2.58)
Adjusted	1.0	0.92 (0.62-1.36)	1.77 (1.18-2.65)
Preeclampsia			
Crude	1.0	1.17 (0.95-1.45)	1.45 (1.13-1.86)
Adjusted	1.0	1.21 (0.98-1.50)	1.74 (1.35-2.25)
Preterm delivery			
Crude	1.0	1.23 (1.02-1.47)	1.25 (1.00-1.56)
Adjusted	1.0	1.22 (1.02-1.47)	1.25 (1.00-1.56)
Perinatal mortality			
Crude	1.0	1.48 (0.71-3.08)	1.14 (0.44-2.98)
Adjusted	1.0	1.47 (0.70-3.03)	1.08 (0.41-2.83)
Cesarean section			
Crude	1.0	1.38 (1.19-1.60)	1.69 (1.40-2.04)
Adjusted	1.0	1.37 (1.18-1.60)	1.67 (1.38-2.03)
Neonatal overweight			
Crude	1.0	1.17 (0.98-1.40)	1.35 (1.09-1.67)
Adjusted	1.0	1.19 (0.99-1.42)	1.36 (1.09-1.69)

*Adjusted for ethnicity, maternal age, height, parity, smoking first trimester, chronic hypertension

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
	X	(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2X	Explain the scientific background and rationale for the investigation being reported
Objectives	3X	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4x	Present key elements of study design early in the paper
Setting	5x	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6x	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
		(b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	7x	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*x	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9x	Describe any efforts to address potential sources of bias
Study size	10x	Explain how the study size was arrived at
Quantitative variables	11x	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12x	(a) Describe all statistical methods, including those used to control for confounding
		(b) Describe any methods used to examine subgroups and interactions
		(c) Explain how missing data were addressed
		(d) If applicable, explain how loss to follow-up was addressed
		(e) Describe any sensitivity analyses
Results		
Participants	13*x	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
		(b) Give reasons for non-participation at each stage
		(c) Consider use of a flow diagram
Descriptive data	14*x	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
		(b) Indicate number of participants with missing data for each variable of interest
		(c) Summarise follow-up time (eg, average and total amount)
Outcome data	15*x	Report numbers of outcome events or summary measures over time
Main results	16x	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
		(b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

Other analyses	17x	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18x	Summarise key results with reference to study objectives
Limitations	19x	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20x	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21x	Discuss the generalisability (external validity) of the study results
Other information		
Funding	22x	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.